129 results on '"Christian H. Geisler"'
Search Results
2. Data from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
- Author
-
Eva Kimby, Birger Christensson, Birgitta Sander, Anne M. Tierens, Martin Maisenhölder, Tuula Lehtinen, Peter de Nully Brown, Christian H. Geisler, Bjørn Østenstad, Marie Nordström, Ola Lindén, Herman Nilsson-Ehle, Martin Erlanson, Hans Hagberg, Harald Holte, Christer Sundström, and Björn Engelbrekt Wahlin
- Abstract
Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is unknown.Experimental Design: Using flow cytometry, we evaluated the T cells in tumors and/or blood in a total of 250 follicular lymphoma patients included in two Nordic Lymphoma Group randomized trials that compared single rituximab with IFN-α2a–rituximab combinations.Results: In univariate analysis, higher levels of CD3+, CD4+, and CD8+ T cells in both tumors and blood correlated with superior treatment responses, and in multivariate analysis, tumor-CD3+ (P = 0.011) and blood-CD4+ (P = 0.029) cells were independent. CD4+ cells were favorable regardless of treatment arm, but CD8+ cells were favorable only in patients treated with single rituximab, because IFN-α2a improved responses especially in patients with low CD8+ cell levels. Higher levels of blood-CD3+ (P = 0.003) and blood-CD4+ (P = 0.046) cells predicted longer overall survival, and higher levels of blood-CD8+ cells longer times to next treatment (P = 0.046).Conclusions: We conclude that therapeutic effects of rituximab are augmented by tumor-associated T cells for rapid responses and by systemic T cells for sustained responses. CD4+ and CD8+ cells are both favorable in patients treated with rituximab. IFN-α2a abrogates the negative impact of few CD8+ cells. Clin Cancer Res; 17(12); 4136–44. ©2011 AACR.
- Published
- 2023
3. Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
- Author
-
Eva Kimby, Birger Christensson, Birgitta Sander, Anne M. Tierens, Martin Maisenhölder, Tuula Lehtinen, Peter de Nully Brown, Christian H. Geisler, Bjørn Østenstad, Marie Nordström, Ola Lindén, Herman Nilsson-Ehle, Martin Erlanson, Hans Hagberg, Harald Holte, Christer Sundström, and Björn Engelbrekt Wahlin
- Abstract
Supplementary Materials and Methods from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
- Published
- 2023
4. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
- Author
-
Francesco Favero, Kirsten Grønbæk, Lone Bredo Pedersen, Arne Kolstad, Christian Winther Eskelund, Joachim Weischenfeldt, Simon Husby, Mats Jerkeman, Christian H. Geisler, F.G. Rodriguez‐Gonzalez, Riikka Räty, and Tobias Wirenfeldt Klausen
- Subjects
0301 basic medicine ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,In patient ,Chemotherapy ,Hematology ,business.industry ,Clonal hematopoiesis ,Cell Biology ,Chemotherapy regimen ,3. Good health ,Haematopoiesis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,business - Abstract
Eskelund et al examined clonal hematopoiesis (CH) in a cohort of patients with mantle cell lymphoma (MCL) treated with first-line chemotherapy and autologous stem cell transplantation. In young, good-risk MCL patients, CH after first-line therapy arises almost entirely from preexisting clones, stabilizes after a period of expansion posttransplantation, and does not negatively impact survival.
- Published
- 2020
5. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
- Author
-
Mette, Dahl, Simon, Husby, Christian W, Eskelund, Søren, Besenbacher, Søren, Fjelstrup, Christophe, Côme, Sara, Ek, Arne, Kolstad, Riikka, Räty, Mats, Jerkeman, Christian H, Geisler, Jørgen, Kjems, Lasse S, Kristensen, and Kirsten, Grønbæk
- Subjects
Male ,Hematopoietic Stem Cell Transplantation ,Lymphoma, Mantle-Cell ,RNA, Circular ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Transplantation, Autologous ,Survival Rate ,Case-Control Studies ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Humans ,Female ,RNA-Seq ,Follow-Up Studies - Abstract
Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL. We profiled the circRNA expression landscape using RNA-sequencing and explored the prognostic potential of 40 abundant circRNAs in samples from the Nordic MCL2 and MCL3 clinical trials, using NanoString nCounter Technology. We report a circRNA-based signature (circSCORE) developed in the training cohort MCL2 that is highly predictive of time to progression (TTP) and lymphoma-specific survival (LSS). The dismal outcome observed in the large proportion of patients assigned to the circSCORE high-risk group was confirmed in the independent validation cohort MCL3, both in terms of TTP (HR 3.0; P = 0.0004) and LSS (HR 3.6; P = 0.001). In Cox multiple regression analysis incorporating MIPI, Ki67 index, blastoid morphology and presence of TP53 mutations, circSCORE retained prognostic significance for TTP (HR 3.2; P = 0.01) and LSS (HR 4.6; P = 0.01). In conclusion, circRNAs are promising prognostic biomarkers in MCL and circSCORE improves identification of high-risk disease among younger patients treated with cytarabine-containing chemoimmunotherapy and autologous stem cell transplant.
- Published
- 2020
6. Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial
- Author
-
Eugen Tausch, Mark-David Levin, Barbara Eichhorst, Tamar Tadmor, Sandra Robrecht, Thomas Illmer, Michael Hallek, Nisha De Silva, Monika Brüggemann, Clemens-Martin Wendtner, Moritz Fürstenau, Julia Von Tresckow, Stephan Stilgenbauer, Caspar da Cunha-Bang, Björn Schöttker, Arnon P. Kater, Christof Schneider, Michael Gregor, Philipp B. Staber, Florian Simon, Anna-Maria Fink, Michael Baumann, Ilse Christiansen, Can Zhang, Kirsten Fischer, Christian Bjørn Poulsen, Carsten Utoft Niemann, Patrick Thornton, Ann Janssens, Matthias Ritgen, Marinus H. J. van Oers, Thomas Noesslinger, and Christian H. Geisler
- Subjects
Oncology ,medicine.medical_specialty ,Venetoclax ,business.industry ,Incidence (epidemiology) ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Reduction (complexity) ,Tumor lysis syndrome ,chemistry.chemical_compound ,chemistry ,Phase (matter) ,Internal medicine ,medicine ,business - Abstract
Background: In early studies of venetoclax (ven) in CLL, severe tumor lysis syndromes (TLS) were observed leading to the implementation of multiple safety measures including a 5-week ramp up schedule. Since then, studies have consistently reported low rates of TLS in ven-treated patients (pts), most likely as a result of strict prophylactic and laboratory monitoring measures. Various lead-in regimens prior to the administration of ven were shown to be feasible and effective in reducing the risk of TLS in pts with CLL. However, no comparison of different pretreatment regimens has been performed so far in a prospective randomized trial. Using the set-up of the GAIA trial, we compared TLS incidence and formal TLS risk reduction between 3 different ven-based combinations. Methods: The phase 3 GAIA (CLL13) trial compared 3 different time-limited ven-based combinations against standard chemoimmunotherapy (CIT) in fit, treatment-naïve pts with CLL. Pts were randomized to receive CIT (FCR in pts ≤65 years; BR in pts >65 years), ven and rituximab (RVe), ven and obinutuzumab (GVe), or ven, obinutuzumab and ibrutinib (GIVe). In RVe, GVe and GIVe, ven was added at cycle 1 day 22 (ramp up day 1) after a 21-day pretreatment with rituximab (1 dose), obinutuzumab (3 doses) or obinutuzumab (3 doses) plus ibrutinib (continuous) (Figure 1A). The safety population (i.e. all pts who received study treatment) of the ven-containing arms was used for this analysis. TLS was reported according to Cairo-Bishop criteria (Cairo M, Bishop M. Br J Haematol. 2004). For TLS risk evaluation, the most recent available CT/MRI and absolute lymphocyte count (ALC) were used. TLS risk was evaluated at baseline and at ramp up day 1, before the first dose of ven. The patients were categorized retrospectively according to the following TLS risk categories: high (any lymph node [LN] with largest diameter ≥10 cm or any LN with largest diameter ≥5 cm and ALC ≥25 G/L), intermediate (any LN ≥5 cm to Results: The safety population of all ven-containing arms comprised of 696 pts (RVe: 237, GVe: 228, GIVe: 231). Baseline TLS risk was high in 22%, 23% and 19% of pts in the RVe, GVe and GIVe arm, intermediate in 62%, 65%, 67% and low in 10.5%, 14.7% and 12.4% of pts, respectively. After the first 21 days of treatment (i.e. at ramp up day 1), the fraction of pts with a reduction in TLS risk varied between the treatment arms with 31.7% (RVe), 71.4% (GVe) and 47.3% (GIVe) of pts decreasing by at least one TLS risk category (Figure 1B). With regard to TLS risk reduction, GVe was superior to RVe (p In total, 36, 30 and 19 cases of TLS occurred in 29 (12.2%), 26 (11.4%) and 19 (8.2%) pts in the RVe, GVe and GIVe arm. The majority of TLS cases were categorized as CTC grade 3 (28 [RVe], 19 [GVe], 12 [GIVe]), only few CTC grade 4 TLS were reported (1 [RVe], 2 [GVe], 3 [GIVe]). There were no cases of fatal TLS and no pts requiring dialysis due to TLS. In the obinutuzumab arms the majority of TLS cases occurred before ramp up day 1 (GVe: 76.7%, GIVe: 68.4%), i.e. before any venetoclax intake, in contrast 80.6% of TLS cases in the RVe arm were reported during ven ramp up (Figure 2). While there was no significant difference in the cumulative TLS incidence between the treatment arms (p=0.334), there was an increase in TLS occurring after ramp up day 1 in the RVe arm compared to GVe (p Conclusions: This analysis represents the first comparison of the formal TLS risk reduction and actual TLS incidence of different ven-based combinations in a randomized trial. GVe led to the highest TLS risk reduction, while the lowest number of TLS cases occurred in the GIVe arm. Most TLS cases in the GVe and GIVe arms occurred before the start of ven. RVe was least effective in reducing TLS risk and in contrast to the obinutuzumab-containing arms, the vast majority of TLS cases was reported during the ven ramp up. The relatively high incidence of TLS in comparison to other trials might partly be a consequence of using different reporting criteria (Cairo-Bishop vs Howard criteria). No fatal TLS occurred in any of the treatment arms. Figure 1 Figure 1. Disclosures Von Tresckow: AbbVie: Honoraria, Other: advisory board, travel grant; Celgene: Other: travel grant; AstraZeneca: Honoraria, Other; Roche: Honoraria, Other: Reasearch support, travel grant; Janssen: Honoraria, Other: Reasearch support, travel grant. Niemann: Novo Nordisk Foundation: Research Funding; CSL Behring, Genmab, Takeda, Octapharma: Consultancy; Abbvie, AstraZeneca, Janssen: Consultancy, Research Funding. Kater: Abbvie: Honoraria, Other: Ad Board, Research Funding; Janssen, AstraZeneca: Other: Ad Board, steering committee, Research Funding; Genmab, LAVA: Other: Ad Board, Steering Committee; BMS, Roche/Genentech: Other: Ad Board, , Research Funding. Staber: Roche: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria; Takeda: Consultancy, Research Funding; MSD: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Incyte: Consultancy, Honoraria, Research Funding; Beigene: Consultancy, Honoraria. Tadmor: Janssen: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Levin: Roche, Janssen, Abbvie: Other: Travel Expenses, Ad-Board. Poulsen: Janssen: Consultancy; Abbvie: Consultancy. Janssens: Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Trael Grant, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy; Beigene, AstraZeneca: Consultancy, Speakers Bureau; Abbvie, Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Noesslinger: AbbVie: Honoraria; Celgene: Honoraria; Roche: Honoraria; Jansen: Honoraria; AstraZeneca: Honoraria; Gilead: Honoraria. Simon: Gilead: Other: Travel support. Fink: AbbVie: Other: travel grant; Janssen: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding; Celgene: Research Funding. Fischer: Abbvie: Honoraria; Roche: Honoraria, Other: Travel Grants. Wendtner: Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Janssen Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Mundipharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding. Ritgen: MSD: Consultancy, Other: Travel support; Chugai: Consultancy; Abbvie: Consultancy, Other: Travel support, Research Funding; Roche: Consultancy, Other: Travel support, Research Funding; Celgene: Other: Travel support. Brüggemann: Amgen: Other: Advisory Board, Travel support, Research Funding, Speakers Bureau; Incyte: Other: Advisory Board; Janssen: Speakers Bureau. Stilgenbauer: AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Honoraria; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Other: Research Support; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Research Funding; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Consultancy. Hallek: Roche: Honoraria, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Mundipharma: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Celgene: Honoraria, Speakers Bureau; Pharmacyclics: Honoraria, Speakers Bureau. Eichhorst: Gilead: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Speakers Bureau; Adaptive Biotechnologies: Speakers Bureau; Hexal: Speakers Bureau; ArQule: Membership on an entity's Board of Directors or advisory committees; Oxford Biomedica (UK): Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; Consultant Department I for Internal Medicine: Consultancy; University Hospital of Cologne: Current Employment. OffLabel Disclosure: The combination of obinutuzumab, venetoclax and ibrutinib is not approved for the treatment of CLL
- Published
- 2021
7. High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial
- Author
-
Eugen Tausch, Barbara Eichhorst, Sandra Robrecht, Marinus H. J. van Oers, Nisha De Silva, Carsten Utoft Niemann, Monika Brüggemann, Patrick Thornton, Julia Von Tresckow, Arnon P. Kater, Caspar da Cunha-Bang, Philipp B. Staber, Anna-Maria Fink, Stephan Stilgenbauer, Can Zhang, Florian Simon, Christian H. Geisler, Matthias Ritgen, Michael Gregor, Kirsten Fischer, Mark-David Levin, Moritz Fürstenau, Michael Hallek, Anke Schilhabel, Clemens-Martin Wendtner, and Tamar Tadmor
- Subjects
Materials science ,medicine.diagnostic_test ,Immunology ,Phase (waves) ,High resolution ,Cell Biology ,Hematology ,Biochemistry ,Minimal residual disease ,DNA sequencing ,Flow cytometry ,medicine ,Sensitivity (control systems) ,Biomedical engineering - Abstract
Background: Venetoclax (ven)-based time-limited combination treatments have yielded high rates of undetectable MRD (uMRD) in patients (pts) with CLL. In correlative analyses, attainment of uMRD status was associated with longer progression-free survival (PFS), making uMRD a robust surrogate parameter for remission duration particularly after time-limited therapy. While MRD is usually assessed by conventional 4-color flow cytometry (FCM) defining uMRD as less than 1 CLL cell in 10 000 leukocytes ( Methods: The phase 3 GAIA (CLL13) trial compared 3 different time-limited ven-based combinations against chemoimmunotherapy (CIT) in fit, treatment-naïve pts with CLL. Pts were randomized to receive CIT for 6 cycles of 28 days each (FCR for pts ≤65 years; BR for pts >65 years), ven and rituximab (RVe), ven and obinutuzumab (GVe), or ven, obinutuzumab and ibrutinib (GIVe), all for 12 cycles with the option for ibrutinib continuation until cycle 36 for pts not obtaining uMRD4. The co-primary endpoints were the rate of uMRD4 at month (MO) 15 (GVe vs CIT) and PFS (GIVe vs CIT). MRD was centrally assessed by FCM at MO2, MO9, MO12 and MO15 in peripheral blood (PB) and at final restaging (RE, two months after the end of treatment) in bone marrow (BM). The following categories were used: high (≥10 -2), intermediate (≥10 -4 to Results: In total, 926 pts were randomized (CIT: 229, RVe: 237, GVe: 229, GIVe: 231). Based on the intention-to-treat (ITT) population, rates of uMRD4 in PB by FCM were 62.0% (CIT), 73.0% (RVe), 88.6% (GVe) and 88.3% (GIVe) at MO9 and 52.0% (CIT), 57.0 (RVe), 86.5% (GVe) and 92.2% (GIVe) at MO15. BM uMRD4 results at RE were 37.1% (CIT), 43.0 (RVe), 72.5% (GVe) and 77.9% (GIVe). HsFCM samples were available for 844 (MO9 PB), 863 (MO15 PB) and 744 (RE BM) pts with median limits of detection (LOD) of 1.6x10 -5 (MO9 PB), 1.4x10 -5 (MO15 PB) and 9.9x10 -6 (RE BM) that were similar between the treatment arms. With hsFCM a lower limit of detection (LOD) of ≤10 -5 was achieved in 364 (MO9) and 477 (MO15) PB samples and in 580 BM samples at RE. 480 (MO9 PB), 386 (MO15 PB) and 164 (RE BM) samples did not reach a LOD of ≤10 -5 and were thus not included in the MRD5-evaluable populations (Figure 1). Among pts with samples evaluable for MRD5 in PB at MO15, 26 of 82 (31.7%, CIT), 45 of 132 (34.1%, RVe), 81 of 131 (61.8%, GVe) and 93 of 132 (70.5%, GIVe) achieved uMRD5. BM uMRD5 rates at RE were 24.2% (23 of 95 pts), 16.1% (27 of 168 pts), 41.7% (65 of 156 pts) and 53.4% (86 of 161 pts), respectively (Figure 2A). The median MRD level at MO9 was lower in CIT, GVe, GIVe (all 1x 10 -5) compared with RVe (2x 10 -5) by hsFCM (Figure 2B). While the obinutuzumab-containing arms stayed at this low level between MO9 and MO15, median MRD levels in CIT and RVe increased to 8.9x 10 -5 (CIT) and 3.1x 10 -5 (RVe) in the same period. The different treatment arms showed distinct patterns of differential clearance of CLL in BM and PB. While the fraction of concordant MRD results between PB and BM at RE was lower in the CIT arm with 14/34 (41.2%), the ven-containing arms showed a similar compartment effect with a proportion of concordant results of 67/108 (62.0%, RVe), 70/101 (69.3%, GVe) and 71/104 (68.3%, GIVe). In 9/16 (56.3%, CIT), 23/36 (63.9%, RVe), 22/63 (34.9%, GVe) and 23/73 (31.5%,GIVe) pts who achieved uMRD5 in PB (RE) MRD was still measurable in BM. More sensitive NGS analyses and detailed correlative analyses are pending and will be presented at the conference. Conclusions: HsFCM improves MRD detection in CLL below 10 -4 in PB and BM by capturing low levels of MRD (≥10 -5 to Figure 1 Figure 1. Disclosures Von Tresckow: Celgene: Other: travel grant; AstraZeneca: Honoraria, Other; Roche: Honoraria, Other: Reasearch support, travel grant; Janssen: Honoraria, Other: Reasearch support, travel grant; AbbVie: Honoraria, Other: advisory board, travel grant. Niemann: CSL Behring, Genmab, Takeda, Octapharma: Consultancy; Abbvie, AstraZeneca, Janssen: Consultancy, Research Funding; Novo Nordisk Foundation: Research Funding. Kater: Genmab, LAVA: Other: Ad Board, Steering Committee; Abbvie: Honoraria, Other: Ad Board, Research Funding; BMS, Roche/Genentech: Other: Ad Board, , Research Funding; Janssen, AstraZeneca: Other: Ad Board, steering committee, Research Funding. Simon: Gilead: Other: Travel support. Fink: AbbVie: Other: travel grant; Janssen: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Research Funding; Celgene: Research Funding. Fischer: Abbvie: Honoraria; Roche: Honoraria, Other: Travel Grants. Wendtner: Mundipharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Janssen Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding; Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel support, Research Funding. Staber: Roche: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria; Takeda: Consultancy, Research Funding; MSD: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Incyte: Consultancy, Honoraria, Research Funding; Beigene: Consultancy, Honoraria. Tadmor: Janssen: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Levin: Roche, Janssen, Abbvie: Other: Travel Expenses, Ad-Board. Stilgenbauer: AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Honoraria; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Other: Research Support; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Research Funding; AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis, Sunesis: Consultancy. Brüggemann: Amgen: Other: Advisory Board, Travel support, Research Funding, Speakers Bureau; Incyte: Other: Advisory Board; Janssen: Speakers Bureau. Hallek: Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau. Ritgen: MSD: Consultancy, Other: Travel support; Chugai: Consultancy; Abbvie: Consultancy, Other: Travel support, Research Funding; Roche: Consultancy, Other: Travel support, Research Funding; Celgene: Other: Travel support. Eichhorst: AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Speakers Bureau; Adaptive Biotechnologies: Speakers Bureau; Hexal: Speakers Bureau; ArQule: Membership on an entity's Board of Directors or advisory committees; Oxford Biomedica (UK): Membership on an entity's Board of Directors or advisory committees; MSD: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Travel, accomodation, expenses, Research Funding, Speakers Bureau; Consultant Department I for Internal Medicine: Consultancy; University Hospital of Cologne: Current Employment. OffLabel Disclosure: The combination of obinutuzumab, venetoclax and ibrutinib is not approved for treatment of CLL
- Published
- 2021
8. Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience
- Author
-
Christian H. Geisler, Anna Laurell, Mats Jerkeman, Åsa Lindberg, Kirsten Grønbæk, Alexandra Albertsson-Lindblad, Christian Winther Eskelund, Arne Kolstad, and Riikka Räty
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Immunology ,Population ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Quality of life ,Internal medicine ,medicine ,Progression-free survival ,10. No inequality ,education ,030304 developmental biology ,0303 health sciences ,education.field_of_study ,business.industry ,Proportional hazards model ,Cell Biology ,Hematology ,medicine.disease ,3. Good health ,Cohort ,Mantle cell lymphoma ,business ,030215 immunology - Abstract
Background: Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality of life (HRQOL) both during active disease and in the long term, and improvement of HRQOL may be one of the most important objectives of cancer therapy. In addition, baseline HRQOL has in other lymphoma populations been shown to be predictive of outcome. Hitherto, there are only few reports on HRQOL in MCL. The primary aim of this study was to explore HRQOL before, during and after chemotherapy in an elderly population with MCL. Secondary aims were to identify predictors for HRQOL, information that can be used for improvement in rehabilitation. Methods: The cohort consisted of patients included in the multicenter open-label phase Ib-II NLG-MCL4 trial (LENA-BERIT), designed to evaluate the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment in elderly patients (>65 years) with MCL. The treatment with R-B stopped after six months, LEN continued for six more months. HRQOL was assessed by the EORTC QLQ-C30 questionnaire pre-treatment, and after 6, 12 and 24 months post study inclusion. For the functional scales and the global quality of life scale a higher score represents a better level of functioning. For the symtom scales and single items, a higher score corresponds to a higher level of symtoms. Patient scores were compared to scores from a reference population sample at baseline. Survival was analysed by Kaplan-Meier estimates, and cox regression multivariate analysis was used to assess survival with adjustments for prognostic factors, age, sex and more. Results: Fifty-one patients were enrolled, 1 patient was excluded based on screen failure. Median age was 71 years (range 62-84), 37 were men (73%). Stratified according to Mantle Cell Lymphoma International Prognostic Index (MIPI), 5 (10%) were low-risk, 18 (38%) intermediate and 26 (52%) high-risk. Follow-up time for living patients were 52 months, and for deceased patients 27 months. Median overall survival time were 52 months. The proportion of patients reporting HRQOL data was at baseline; 48 (96%), after 6 months; 33 (83%), after 12 months; 27 (89%), and after 24 months; 12 (75%). During the first six months of treatment, several functional scores deteriorated, and after 12 months it had stabilised at baseline level or better. The global health status (QoL) improved at 12 months after diagnosis, but then dropped to baseline levels after 2 years. Before treatment, patients exhibited levels of the symptom scores, comparable to the reference population. Six months after start of therapy, the scores for pain, dyspnoea and insomnia were improved, while appetite loss and diarrhoea were impaired. After 12 months, the symptom scales improved to a level superior compared both to baseline and the reference population. The population was divided into two groups, with the median as cut-off values. In the multivariate analysis, including MIPI, gender and the presence of TP53 mutation, impaired pre-treatment physical function, role function and elevated pain score were independent prognostic markers for overall survival. Role function and pain were also independent prognostic markers for progression free survival. Conclusion: In this population of elderly patients with MCL, pre-treatment HRQOL was similar to the reference population. During treatment, HRQOL deteriorated, but reverted to the same level as the reference population after treatment. Pre-treatment physical and role function and pain were independent factors associated with overall survival. These novel findings may be used to design support during treatment and improve rehabilitation. Figure Disclosures Jerkeman: Roche: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Gilead: Research Funding; Abbvie: Research Funding.
- Published
- 2020
9. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
- Author
-
Peter de Nully Brown, Simon Husby, Jakob Werner Hansen, Kirsten Grønbæk, Mats Jerkeman, Arne Kolstad, Christian Winther Eskelund, Carsten Utoft Niemann, Riikka Räty, Maj Westman, Mette K. Andersen, Sara Ek, Christina Dahl, Per Guldberg, Christian H. Geisler, Catja Freiburghaus, Anja Pedersen, Carmen P. Montano-Almendras, and Lone Bredo Pedersen
- Subjects
Oncology ,medicine.medical_specialty ,Immunology ,Blastoid ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,CDKN2A ,Chemoimmunotherapy ,hemic and lymphatic diseases ,Internal medicine ,medicine ,neoplasms ,biology ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,biology.organism_classification ,3. Good health ,Lymphoma ,Transplantation ,chemistry ,030220 oncology & carcinogenesis ,Ibrutinib ,Rituximab ,Mantle cell lymphoma ,business ,030215 immunology ,medicine.drug - Abstract
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are still unable to identify patients who will not benefit from the current standard of care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger patients with MCL from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53 (11%) and NOTCH1 (4%), and deletions of TP53 (16%) and CDKN2A (20%), were significantly associated with inferior outcomes (together with MIPI, MIPI-c, blastoid morphology, and Ki67 > 30%); however, in multivariate analyses, only TP53 mutations (HR, 6.2; P 30%, blastoid morphology, MIPI high-risk, and inferior responses to both induction- and high-dose chemotherapy. In conclusion, we show that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to regimens including cytarabine, rituximab, and autologous stem-cell transplant (ASCT). We suggest patients with MCL should be stratified according to TP53 status, and that patients with TP53 mutations should be considered for experimental frontline trials exploring novel agents.
- Published
- 2017
10. Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
- Author
-
Mats Jerkeman, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Jacob H. Christensen, Hanne Kuitunen, Christian Winther Eskelund, Kirsten Groenbaek, Carsten Utoft Niemann, Christian H. Geisler, and Arne Kolstad
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Abstract
Introduction: In spite of improvements in treatment of mantle cell lymphoma (MCL), this is still considered an incurable lymphoma entity, and the majority of patients eventually relapse. Ibrutinib is a very active agent in MCL, but in vitro has been shown to partially antagonize the activity of rituximab, by suppression of NK cell activity and subsequent ADCC. Lenalidomide, on the other hand, improves rituximab-induced ADCC. In this multi-centre open-label phase II trial, we evaluated safety and efficacy of this triplet combination in patients with relapsed or refractory MCL. Methods: Patients with MCL, relapsing after or refractory to at least one rituximab-containing chemotherapy regimen, WHO PS 0-3, and measurable disease were eligible. The primary endpoint was maximal overall response rate (ORR) measured with CT and PET/CT. Minimal residual disease (MRD) monitoring by PCR was performed during follow-up, according to EuroMRD criteria. Ion Torrent sequencing of the most frequently mutated genes in MCL was performed on frozen tumor cells from bone marrow at time of relapse. Health-related quality of life was assessed by the EORTC-QLQ C30 questionnaire before and during treatment. Treatment schedule: Induction phase: Up to twelve 28-day cycles with: Lenalidomide 15 mg p o daily, days 1-21, Ibrutinib 560 mg p o days 1-28, Rituximab 375 mg/m2 i v day 1 in cycle 1, then 1400 mg s c (or 375 mg/m2i v) days 8, 15 and 22 in cycle 1, then day 1 in cycles 3, 5, 7, 9 and 11. Maintenance phase: For patients in CR, PR or SD, not in need of other treatment, given until progression, cycle duration 56 days. Ibrutinib: 560 mg p o days 1-56, 2. Rituximab 1400 mg s c (or 375 mg/m2i v) day 1 of each cycle. Results: Accrual of 50 pts was completed in June 2016, at 10 centres in Sweden, Norway, Denmark and Finland. The median age was 69.5 years, with a median MIPI score of 6.2. Patients had received a median of two previous regimens, four had progressed after single agent ibrutinib, and three had received prior allo-SCT. A TP53 mutation was detected in 11 of 49 evaluable cases (22%), 8 cases were of blastoid/pleomorphic histology, and 22 of 40 evaluable cases had a Ki67 >30%. Treatment emergent-AEs of any grade in ≥20% of patients were rash (24%) and fatigue (20%). Five pts (10%) experienced rash grade 3, mainly during cycle 1. Hematological toxicity was generally of low grade, apart from grade 3-4 neutropenia in 5 patients. One patient died due to possible treatment-related toxicity (septic shock). In total, 27 patients achieved CR (54%) and 10 PR (20%). Among evaluable patients with a TP53 mutation, blastoid/pleomorphic histology or Ki67 >30%, the CR rates were 7/11 (64%), 15/8 (62%) and 11/22 (50%), respectively. After a median follow-up of 40 months, the median PFS is 18 months (95% CI 6.5-28), and median OS 47 months (95% CI 30-64). Patients with a detectable TP53 mutation at relapse (n=11) had a median PFS of 13 months (95% CI 4.2-21), whereas pts without a TP53 mutation had a median PFS of 34 months (95% CI 8.3-60). Of the 28 patients evaluable for MRD at 6 months, 15/27 (56%) patients achieved molecular remission in blood and 12/28 (43%) in bone marrow. After 12 months, MRD-negativity in BM was 68% (13/19). Out of 4 patients with TP53-mutated MCL, 2 were MRD-negative in BM after 12 months, as well as 2 out of 4 patients with blastoid/pleomorphic histology. By self-reported HRQOL, a lower level of emotional functioning (EF), as well as a higher level of pain (PA) at baseline, was associated with inferior PFS. In addition, low EF was associated with inferior OS. By a Cox regression multivariable analysis, including MIPI, TP53, histology, Ki67, EF and PA, only MIPI was prognostic for PFS or OS with this regimen. Conclusions: The combination of ibrutinib, lenalidomide and rituximab has been shown to be an active and well tolerated regimen in this cohort of high risk R/R MCL, associated with a high rate of molecular remission. The activity in TP53 mutated MCL is lower than in unmutated disease, but this regimen may still serve as an option for a bridge to an allogeneic transplantation or CAR-T therapy in this category of patients. Disclosures Jerkeman: Roche: Research Funding; Abbvie: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Gilead: Research Funding. Hutchings:Genmab: Honoraria; Genmab: Consultancy; Takeda: Consultancy; Roche: Research Funding; Celgene: Research Funding; Daiichi: Research Funding; Sankyo: Research Funding; Genmab: Research Funding; Janssen: Research Funding; Novartis: Research Funding; Sanofi: Research Funding; Takeda: Research Funding; Roche: Honoraria; Roche: Consultancy; Takeda: Honoraria.
- Published
- 2020
11. A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies
- Author
-
Kirsten Grønbæk, Arne Kolstad, Lasse Sommer Kristensen, Christian H. Geisler, Sara Ek, Riikka Räty, Christophe Côme, Mette Dahl, Simon Husby, Mats Jerkeman, and Christian Winther Eskelund
- Subjects
Mutation ,medicine.medical_treatment ,Immunology ,RNA ,Cancer ,RNA-Seq ,Cell Biology ,Hematology ,Biology ,medicine.disease ,medicine.disease_cause ,Biochemistry ,3. Good health ,Lymphoma ,Cancer immunotherapy ,Circular RNA ,medicine ,Cancer research ,Mantle cell lymphoma - Abstract
INTRODUCTION: Circular RNAs (circRNAs) are covalently closed endogenous RNA molecules with tissue- and disease specific expression patterns, that are emerging as potential diagnostic and prognostic biomarkers. These molecules exert diverse regulatory functions, and several studies have reported prognostic relevance and functional significance of circRNAs in cancer. However, no studies have yet examined the role of circRNAs in Mantle Cell Lymphoma (MCL). We have previously shown that the Nanostring nCounter technology enables specific, sensitive and accurate quantification of circRNAs in formalin-fixed, paraffin-embedded (FFPE) tissue samples from patients (Dahl et al, 2018). Here, we quantified circRNA expression in MCL tumors to address whether certain circRNAs could serve as prognostic markers in MCL. Samples were obtained from patients treated in the two Nordic clinical trials MCL2 and MCL3, all treated with immuno-chemotherapy and autologous stem cell transplant, which due to the improved prognosis observed with this regimen, remains the current standard of care. MATERIALS AND METHODS: We profiled the genome-wide circRNA expression in MCL using high-throughput RNA-sequencing (RNA-seq) of 14 diagnostic MCL samples, from which high-quality RNA from lymph nodes with MCL tumor infiltration was available. Based on these data, we designed assays for analyses of 41 differentially expressed circRNAs and quantified the expression using the NanoString nCounter technology. We examined the prognostic potential of individual circRNAs in a training cohort of 75 patients (MCL2) and confirmed these results in an independent, but similarly treated, validation cohort of 90 patients (MCL3). RESULTS: The total cohort consisted of 165 previously untreated MCL patients In our training cohort we identified seven circRNAs that were significantly associated with both progression-free survival (PFS), TTP, overall survival (OS) and lymphoma specific survival (LSS). We dichotomized expression values of each individual circRNA and examined the prognostic value in the validation cohort MCL3. Only one (circRAB11FIP1) of the seven circRNAs identified in MCL2 retained prognostic value in MCL3. As shown in Figure 1, univariate analysis revealed that low circRAB11FIP1 expression was significantly associated with TTP in MCL2 (HR=5.1, [2.5;10.4], p Finally, we performed a multivariate cox regression analysis of the entire cohort and found that circRAB11FIP1 was an independent prognostic factor for TTP, even when adjusting for MIPI and ki67-index (HR=2.36[1.3;4.4], p CONCLUSION: Our study showed that low circRAB11FIP1 was significantly associated with shorter TTP, even when adjusting for known prognostic factors, indicating that circRAB11FIP1 could play a specific role in the pathogenesis of MCL. CircRAB11FIP1 originates from exon 2 of the host gene RAB11-Family Interacting Protein 1 located on chromosome 8, and no studies have yet examined the functional role of this circRNA. Interestingly, we found that low circRAB11FIP1 was significantly associated with the presence of TP53 mutations. This warrants future studies to examine whether there is a functional link between circRAB11FIP1 and TP53 in MCL, which may help explain why patients with TP53 mutations have an exceedingly poor prognosis. Figure Disclosures Kolstad: Merck: Research Funding; Nordic Nanovector: Membership on an entity's Board of Directors or advisory committees, Research Funding. Jerkeman:Janssen: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Acerta: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding.
- Published
- 2019
12. Deep targeted sequencing of
- Author
-
Christian, Brieghel, Savvas, Kinalis, Christina W, Yde, Ane Y, Schmidt, Lars, Jønson, Michael A, Andersen, Caspar, da Cunha-Bang, Lone B, Pedersen, Christian H, Geisler, Finn C, Nielsen, and Carsten U, Niemann
- Subjects
Male ,endocrine system diseases ,High-Throughput Nucleotide Sequencing ,Middle Aged ,Leukemia, Lymphocytic, Chronic, B-Cell ,Disease-Free Survival ,Article ,Survival Rate ,Gene Frequency ,Mutation ,Humans ,Female ,Chronic Lymphocytic Leukemia ,Tumor Suppressor Protein p53 ,neoplasms ,Alleles ,Aged - Abstract
In chronic lymphocytic leukemia, TP53 mutations and deletion of chromosome 17p are well-characterized biomarkers associated with poor progression-free and overall survival following chemoimmunotherapy. Patients harboring low burden TP53 mutations with variant allele frequencies of 0.3-15% have been shown to have similar dismal outcome as those with high burden mutations. We here describe a highly sensitive deep targeted next-generation sequencing assay allowing for the detection of TP53 mutations as low as 0.2% variant allele frequency. Within a consecutive, single center cohort of 290 newly diagnosed patients with chronic lymphocytic leukemia, deletion of chromosome 17p was the only TP53 aberration significantly associated with shorter overall survival and treatment-free survival. We were unable to demonstrate any impact of TP53 mutations, whether high burden (variant allele frequency >10%) or low burden (variant allele frequency ≤10%), in the absence of deletion of chromosome 17p. In addition, the impact of high burden TP53 aberration (deletion of chromosome 17p and/or TP53 mutation with variant allele frequency >10%) was only evident for patients with IGHV unmutated status; no impact of TP53 aberrations on outcome was seen for patients with IGHV mutated status. In 61 patients at time of treatment, the prognostic impact of TP53 mutations over 1% variant allele frequency could be confirmed. This study furthers the identification of a clinical significant limit of detection for robust TP53 mutation analysis in chronic lymphocytic leukemia. Multicenter studies are needed for validation of ultra-sensitive TP53 mutation assays in order to define and implement a technical as well as a clinical lower limit of detection.
- Published
- 2018
13. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
- Author
-
Richard W. Childs, Gerald E. Marti, Irina Maric, Thomas E. Hughes, Stefania Pittaluga, Nakhle S. Saba, Adrian Wiestner, Katherine R. Calvo, Christian H. Geisler, Sarah E. M. Herman, Stephanie Housel, Janet Valdez, Constance M. Yuan, Georg Aue, Maryalice Stetler-Stevenson, Xin Tian, Pia Nierman, Lone Bredo Pedersen, Clare Sun, Mohammed Farooqui, Inhye E. Ahn, Carsten Utoft Niemann, Susan Soto, and Jennifer Lotter
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Immunology ,Phases of clinical research ,Antineoplastic Agents ,Kaplan-Meier Estimate ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Piperidines ,Bone Marrow ,Internal medicine ,Medicine ,Humans ,Adverse effect ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Adenine ,Atrial fibrillation ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Minimal residual disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Confidence interval ,Pyrimidines ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Ibrutinib ,Cohort ,Pyrazoles ,Female ,business ,Progressive disease ,030215 immunology ,Follow-Up Studies - Abstract
The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had TP53 aberration (TP53 cohort) and 35 were enrolled because of age 65 years or older (elderly cohort). Both cohorts included patients with treatment-naive (TN) and relapsed/refractory (RR) CLL. With the median follow-up of 4.8 years, 49 (57.0%) of 86 patients remain on study. Treatment was discontinued for progressive disease in 20 (23.3%) patients and for adverse events in 5 (5.8%). Atrial fibrillation occurred in 18 (20.9%) patients for a rate of 6.4 per 100 patient-years. No serious bleeding occurred. The overall response rate at 6 months, the primary study endpoint, was 95.8% for the TP53 cohort (95% confidence interval, 85.7%-99.5%) and 93.9% for the elderly cohort (95% confidence interval, 79.8%-99.3%). Depth of response improved with time: at best response, 14 (29.2%) of 48 patients in the TP53 cohort and 9 (27.3%) of 33 in the elderly cohort achieved a complete response. Median minimal residual disease (MRD) in peripheral blood was 3.8 × 10-2 at 4 years, with MRD-negative (
- Published
- 2017
14. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator
- Author
-
Simon Husby, Mats Ehinger, Christian Garde, Jack B. Cowland, Jan Delabie, Christian H. Geisler, Arne Kolstad, Ulrik Ralfkiaer, Sara Ek, Lone Bredo Pedersen, Riikka Räty, Roza Zandi, Christopher T. Workman, Erik Clasen-Linde, Christer Sundström, Kirsten Grønbæk, Marja-Liisa Karjalainen-Lindsberg, Peter de Nully Brown, Anna Laurell, Mats Jerkeman, and Anja Pedersen
- Subjects
Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Apoptosis ,Lymphoma, Mantle-Cell ,Transfection ,Bioinformatics ,Biochemistry ,Disease-Free Survival ,International Prognostic Index ,Cell Line, Tumor ,hemic and lymphatic diseases ,Internal medicine ,microRNA ,Biomarkers, Tumor ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Aged ,Cell Proliferation ,Chemotherapy ,Hematology ,business.industry ,Cell growth ,Cell Biology ,Middle Aged ,Prognosis ,medicine.disease ,Up-Regulation ,Lymphoma ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,Female ,Mantle cell lymphoma ,business - Abstract
Recent studies show that mantle cell lymphoma (MCL) express aberrant microRNA (miRNA) profiles; however, the clinical effect of miRNA expression has not previously been examined and validated in large prospective homogenously treated cohorts. We performed genome-wide miRNA microarray profiling of 74 diagnostic MCL samples from the Nordic MCL2 trial (screening cohort). Prognostic miRNAs were validated in diagnostic MCL samples from 94 patients of the independent Nordic MCL3 trial (validation cohort). Three miRNAs (miR-18b, miR-92a, and miR-378d) were significantly differentially expressed in patients who died of MCL in both cohorts. MiR-18b was superior to miR-92a and miR-378d in predicting high risk. Thus, we generated a new biological MCL International Prognostic Index (MIPI-B)-miR prognosticator, combining expression levels of miR-18b with MIPI-B data. Compared to the MIPI-B, this prognosticator improved identification of high-risk patients with regard to cause-specific, overall, and progression-free survival. Transfection of 2 MCL cell lines with miR-18b decreased their proliferation rate without inducing apoptosis, suggesting that miR-18b may render MCL cells resistant to chemotherapy by decelerating cell proliferation. We conclude that overexpression of miR-18b identifies patients with poor prognosis in 2 large prospective MCL cohorts and adds prognostic information to the MIPI-B. MiR-18b may reduce the proliferation rate of MCL cells as a mechanism of chemoresistance.
- Published
- 2015
15. Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
- Author
-
John Arne Nesheim, Christian H. Geisler, Erlend B. Smeland, Hans Martin Mohn, Håvard E. Danielsen, Harald Holte, John Maddison, Arne Kolstad, Jan Delabie, Yngvild Nuvin Blaker, Knut Liestøl, Tarjei S. Hveem, and Marianne Brodtkorb
- Subjects
Histology ,Proliferation index ,biology ,business.industry ,Cell Count ,Lymphoma, Mantle-Cell ,General Medicine ,Gold standard (test) ,Routine practice ,medicine.disease ,Pathology and Forensic Medicine ,Cohort Studies ,Ki-67 Antigen ,Ki-67 ,Image Processing, Computer-Assisted ,biology.protein ,Humans ,Medicine ,Mantle cell lymphoma ,Continuous parameter ,Image analysis ,business ,Nuclear medicine ,Cell Proliferation ,Automated method - Abstract
Aims Manual counting of the fraction of Ki-67-positive cells (the Ki-67 index) in 1000 tumour cells is considered the ‘gold standard’ to predict prognosis in mantle cell lymphoma (MCL). This time-consuming method is replaced by the faster, but less accurate, semiquantitative estimation in routine practice. The aim of this study was to investigate the use of computerized image analysis software for scoring of Ki-67 in MCL. Methods and results We developed an automated method for determining the Ki-67 index by computerized image analysis and tested it using a cohort of 62 MCL patients. The data were compared to Ki-67 scores obtained by semiquantitative estimation and image-based manual counting. When using the Ki-67 index as a continuous parameter, both image-based manual counting and computerized image analysis were related inversely to survival (P = 0.020 and P = 0.025, respectively). Ki-67 index obtained by semiquantitative estimation was not associated significantly with survival (P = 0.093). The results were validated in a second patient cohort with similar results. Conclusion Computerized image analysis of the Ki-67 index in MCL is an attractive alternative to semiquantitative estimation and can be introduced easily in a routine diagnostic setting for risk stratification in MCL.
- Published
- 2015
16. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
- Author
-
Eva Minga, Karin E. Smedby, Lesley-Ann Sutton, Nicholas Chiorazzi, Myriam Boudjogra, Kostas Stamatopoulos, Karla Plevová, Lone Bredo Pedersen, Zadie Davis, Lydia Scarfò, Andreas Agathangelidis, Monica Facco, Achilles Anagnostopoulos, Maria Chatzouli, Chrysoula Belessi, Athina Tsanousa, Panagiotis Baliakas, Kirsten van Lom, Lefteris Angelis, Yorick Sandberg, Gunnar Juliusson, Diane F. Jelinek, Fie Juhl Vojdeman, Anne Gardiner, Panagiotis Panagiotidis, Anton W. Langerak, Florence Nguyen-Khac, Hana Skuhrová Francová, Frederic Davi, Denis Moreno, Silvio Veronese, Richard Rosenquist, Marie-Paule Lefranc, Nikos Darzentas, Šárka Pospíšilová, Véronique Giudicelli, Xiao-Jie Yan, Charles C. Chu, Christian H. Geisler, Larry Mansouri, David Oscier, Mark Catherwood, Marco Montillo, Anastasia Hadzidimitriou, Livio Trentin, Paolo Ghia, Tait D. Shanafelt, Tatiana Tzenou, Baliakas, P, Agathangelidis, A, Hadzidimitriou, A, Sutton, La, Minga, E, Tsanousa, A, Scarfò, L, Davis, Z, Yan, Xj, Shanafelt, T, Plevova, K, Sandberg, Y, Vojdeman, Fj, Boudjogra, M, Tzenou, T, Chatzouli, M, Chu, Cc, Veronese, S, Gardiner, A, Mansouri, L, Smedby, Ke, Pedersen, Lb, Moreno, D, Van Lom, K, Giudicelli, V, Francova, H, Nguyen Khac, F, Panagiotidis, P, Juliusson, G, Angelis, L, Anagnostopoulos, A, Lefranc, Mp, Facco, M, Trentin, L, Catherwood, M, Montillo, M, Geisler, Ch, Langerak, Aw, Pospisilova, S, Chiorazzi, N, Oscier, D, Jelinek, Df, Darzentas, N, Belessi, C, Davi, F, Ghia, PAOLO PROSPERO, Rosenquist, R, Stamatopoulos K. Ghia P., is Co senior author, Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Università Vita-Salute San Raffaele, Milan, Italy, Division of Molecular Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy, Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece, Department of Informatics, Aristotle University of Thessaloniki, Thessaloniki, Greece, Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom, The Feinstein Institute for Medical Research, Mayo Clinic [Rochester], Central European Institute of Technology [Brno] (CEITEC MU), Brno University of Technology [Brno] (BUT), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Department of Hematology, Rigshospitalet, Copenhagen, Denmark, Service d'Hématologie Biologique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), First Department of Propaedeutic Medicine, University of Athens, Athens, Greece, Hematology Department, Nikea General Hospital, Piraeus, Greece, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Lund, Sweden, Hematology Department and Hematopoietic Cell Transplantation Unit, Georgios Papanicolaou Hospital, Thessaloniki, Greece, Universita degli Studi di Padova, Department of Hemato-Oncology, Belfast City Hospital, Belfast, United Kingdom, Immunology, and Hematology
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Immunology ,B-cell receptor ,Gene Rearrangement, B-Lymphocyte, Heavy Chain ,Antineoplastic Agents ,Biology ,Biochemistry ,Time-to-Treatment ,Genetic Heterogeneity ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,10. No inequality ,ComputingMilieux_MISCELLANEOUS ,Survival analysis ,Aged ,030304 developmental biology ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,B-Lymphocytes ,0303 health sciences ,Lymphoid Neoplasia ,Hematology ,Gene Expression Regulation, Leukemic ,Genetic heterogeneity ,Cell Biology ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Treatment Outcome ,030220 oncology & carcinogenesis ,biology.protein ,Immunoglobulin heavy chain ,Female ,Somatic Hypermutation, Immunoglobulin ,Antibody ,Immunoglobulin Heavy Chains ,IGHV@ - Abstract
An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset # 2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset # 2. Within subset # 2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset # 2/IGHV3-21 was enriched for IGHV-unmutated cases (P =.002). Subset # 2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset # 2/IGHV3-21 (22 vs 60 months, P =.001). No such difference was observed between non-subset # 2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset # 2 emerges as uniformly aggressive, contrasting non-subset # 2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
- Published
- 2015
17. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
- Author
-
Jan Walewski, Michael Unterhalt, Christian H. Geisler, Michael Hallek, Martin Dreyling, J.K. Doorduijn, B. van der Holt, Vincent Ribrag, Anna Laurell, Johanna Kluin-Nelemans, Gilles Salles, Arne Kolstad, Wolfram Klapper, Mats Jerkeman, Michal Szymczyk, Christiane Pott, M. B. Van't Veer, R. Raty, Eva Hoster, Johannes Bloehdorn, Olivier Hermine, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Schleswig-Holstein, Department of Medicine, Helsinki University Central Hospital, III. Medizinische Klinik, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Technische Universität München [München] (TUM), Hematology, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)
- Subjects
Melphalan ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lymphoma ,BEAM ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,IMMUNOCHEMOTHERAPY ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,Internal medicine ,Germany ,medicine ,Registries ,Etoposide ,ComputingMilieux_MISCELLANEOUS ,PROGNOSTIC INDEX ,Carmustine ,business.industry ,Cytarabine ,Hematology ,Total body irradiation ,RESCUE ,medicine.disease ,3. Good health ,Surgery ,030220 oncology & carcinogenesis ,SURVIVAL ,Medicine ,Mantle cell lymphoma ,epidemiology ,pathology ,France ,business ,Chemoradiotherapy ,030215 immunology ,medicine.drug - Abstract
In patients with mantle cell lymphoma (MCL) up to 65 years, recommended first-line treatment consists of immuno-chemotherapy including high-dose cytarabine (HA), followed by autologous stem cell transplantation (ASCT) in complete (CR) or partial remission (PR).1 However, it remains unclear whether total body irradiation (TBI) should be part of conditioning before ASCT.1 A large registry study by the European Society for Blood and Marrow Transplantation (EBMT) including 418 MCL patients reported a significantly reduced relapse incidence after TBI in comparison to a non-TBI conditioning (mostly carmustine, etoposide, cytarabine, and melphalan, BEAM), but only for patients transplanted in first PR.2 In contrast, a single-center evaluation of 73 MCL patients who underwent ASCT did not find a significant PFS difference according to the use of TBI vs BEAM.3 A recently published consensus project by EBMT/European MCL Network involving twelve expert clinicians showed that, while consensus was achieved on ASCT as standard first-line consolidation therapy, no consensus was reached on the role of TBI.4 Three recently completed prospective studies including untreated MCL patients up to 65 years investigated the efficacy of HA-containing immuno-chemotherapy followed by ASCT: Nordic MCL2,5, 6 HOVON-45(ref. 7) and European MCL Younger.8, 9 We combined the individual patient data from these studies to compare the long-term clinical outcome of MCL patients transplanted without TBI (Nordic MCL2 and HOVON-45) vs with TBI (MCL Younger, experimental HA-containing arm).
- Published
- 2016
18. Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia
- Author
-
Richard Rosenquist, Ann-Charlotte Bergh, Kostas Stamatopoulos, Anders Rosén, Chamilly Evaldsson, Christian H. Geisler, and Lone Bredo Pedersen
- Subjects
Chronic lymphocytic leukemia ,B-cell receptor ,Immunoglobulin Variable Region ,Receptors, Antigen, B-Cell ,Biology ,Ligands ,Autoantigens ,Antigen ,medicine ,Humans ,Gene Silencing ,Receptor ,Interleukin-6 ,Cell Cycle ,Interleukin-2 Receptor alpha Subunit ,Editorials ,Articles ,Hematology ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Interleukin-10 ,Toll-Like Receptor 9 ,Lipoproteins, LDL ,Interleukin 10 ,Immunoglobulin M ,Immunoglobulin J-Chains ,Immunology ,Calcium ,B7-2 Antigen ,Receptor clustering ,Immunoglobulin Heavy Chains ,IGHV@ ,Protein Binding - Abstract
Chronic lymphocytic leukemia B cells express auto/xeno antigen-reactive antibodies that bind to self-epitopes and resemble natural IgM antibodies in their repertoire. One of the antigenic structures recognized is oxidation-induced malonedialdehyde that is present on low-density lipoprotein, apoptotic blebs, and on certain microbes. The poor-prognostic stereotyped subset #1 (Clan I IGHV genes-IGKV1(D)-39) express IgM B-cell receptors that bind oxidized low-density lipoprotein. In this study, we have used for the first time this authentic cognate antigen for analysis of downstream B-cell receptor-signal transduction events, since it is more faithful to B-cell physiology than anti-IgM. Multivalent oxidized low-density lipoprotein showed specific binding to subset #1 IgM/IgD B-cell receptors, whereas native low-density lipoprotein did not. The antigen binding induced prompt receptor clustering followed by internalization. However, the receptor-signal transduction was silenced, revealing no Ca(2+) mobilization or cell-cycle entry, while phosphorylated extracellular-regulated kinase 1/2 basal levels were high and could not be elevated further by oxidized low-density lipoprotein. Interestingly, B-cell receptor responsiveness was recovered after 48-h culture in the absence of antigen in half of the cases. Toll-like receptor 9-ligand was found to breach the B-cell receptor-signaling incompetence in 5 of 12 cases pointing to intra-subset heterogeneity. Altogether, this study supports B-cell receptor unresponsiveness to cognate self-antigen on its own in poor-prognostic subset #1 chronic lymphocytic leukemia, indicating that these cells proliferate by other mechanisms that may override B-cell receptor silencing brought about in a context of self-tolerance/anergy. These novel findings have implications for the understanding of chronic lymphocytic leukemia pathobiology and therapy.
- Published
- 2014
19. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
- Author
-
Simon Rule, Umberto Vitolo, Martin Dreyling, Dolores Caballero, Olivier Hermine, S. Le Gouill, Paolo Corradini, Eva Kimby, Peter Dreger, Michele Ghielmini, Christian H. Geisler, and Stephen P. Robinson
- Subjects
Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Transplantation Conditioning ,Consensus Development Conferences as Topic ,Lymphoma, Mantle-Cell ,Transplantation, Autologous ,Antibodies, Monoclonal, Murine-Derived ,Recurrence ,hemic and lymphatic diseases ,medicine ,Humans ,Transplantation, Homologous ,business.industry ,Remission Induction ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Hematology ,Total body irradiation ,medicine.disease ,Minimal residual disease ,Surgery ,Lymphoma ,Europe ,Transplantation ,Treatment Outcome ,Oncology ,Positron-Emission Tomography ,Monoclonal ,Mantle cell lymphoma ,Rituximab ,Immunotherapy ,business ,Whole-Body Irradiation ,medicine.drug - Abstract
The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in 'low-risk' patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.
- Published
- 2014
20. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- Author
-
Lone Bredo Pedersen, Irina Maric, Georg Aue, Andrew Lipsky, Adrian Wiestner, Jade Jones, Mohammed Farooqui, Sarah E. M. Herman, Delong Liu, Rashida Z. Mustafa, Susan Soto, Christian H. Geisler, Janet Valdez, Sabrina Martyr, Katherine R. Calvo, Carsten Utoft Niemann, Nakhle S. Saba, Gerald E. Marti, and Jennifer Gyamfi
- Subjects
Male ,safety ,Cancer Research ,Lymphocytosis ,Chronic lymphocytic leukemia ,Blood viscosity ,Receptors, Antigen, B-Cell ,Spleen ,Biology ,Models, Biological ,Article ,Hemoglobins ,chemistry.chemical_compound ,Piperidines ,medicine ,Humans ,Lymphocyte Count ,Aged ,Adenine ,Ibrutinib ,Hematology ,Blood Viscosity ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Tumor Burden ,Leukemia ,Pyrimidines ,medicine.anatomical_structure ,Oncology ,chemistry ,Immunology ,Pyrazoles ,Female ,Lymph ,Bone marrow ,medicine.symptom ,Signal Transduction - Abstract
Ibrutinib and other targeted inhibitors of B-cell receptor signaling achieve impressive clinical results for patients with chronic lymphocytic leukemia (CLL). A treatment-induced rise in absolute lymphocyte count (ALC) has emerged as a class effect of kinase inhibitors in CLL and warrants further investigation. We here report correlative studies in 64 patients with CLL treated with ibrutinib. We quantified tumor burden in blood, lymph nodes, spleen, and bone marrow, assessed phenotypic changes of circulating cells, and measured whole blood viscosity. With just one dose of ibrutinib the average increase in ALC was 66%, and in over 40% of patients the ALC peaked within 24 hours of initiating treatment. Circulating CLL cells on day 2 showed increased Ki67 and CD38 expression, indicating an efflux of tumor cells from the tissue compartments into the blood. The kinetics and degree of the treatment-induced lymphocytosis was highly variable; interestingly in patients with a high baseline ALC the relative increase was mild and resolution rapid. After two cycles of treatment the disease burden in lymph node, bone marrow, and spleen decreased irrespective of the relative change in ALC. Whole blood viscosity was dependent on both ALC and hemoglobin. No adverse events were attributed to the lymphocytosis.
- Published
- 2014
21. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
- Author
-
Mars B. van't Veer, Eva Kimby, Jesper Jurlander, Geir E. Tjønnfjord, Martine C. J. Abrahamse-Testroote, Jeanette K. Doorduijn, Tomas Kozak, Maija Itälä Remes, Ka Lung Wu, Wendimagegn Ghidey Alemayehu, Christian H. Geisler, Marinus H. J. van Oers, Aaron Polliack, Shulamiet Wittebol, Jan Walewski, Hematology, AII - Amsterdam institute for Infection and Immunity, CCA -Cancer Center Amsterdam, and Clinical Haematology
- Subjects
Male ,medicine.medical_specialty ,Cyclophosphamide ,CD52 ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,Immunology ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,Biochemistry ,Gastroenterology ,Disease-Free Survival ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Progression-free survival ,Alemtuzumab ,Aged ,Chemotherapy ,business.industry ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Fludarabine ,Leukemia ,Female ,business ,Vidarabine ,medicine.drug - Abstract
The randomized Haemato Oncology Foundation for Adults in The Netherlands 68 phase 3 trial compared front-line chemotherapy with chemotherapy plus the CD52 monoclonal antibody alemtuzumab for high-risk chronic lymphocytic leukemia, defined as at least 1 of the following: unmutated immunoglobulin heavy chain genes, deletion 17p or 11q, or trisomy 12. Fit patients were randomized to receive either 6 28-day cycles of oral FC chemotherapy (days 1 through 3: fludarabine 40 mg/m(2) per day and cyclophosphamide 250 mg/m(2) per day: n = 139) or FC plus subcutaneous alemtuzumab 30 mg day 1 (FCA, n = 133). FCA prolonged the primary end point, progression-free survival (3-year progression-free survival 53 vs 37%, P = .01), but not the secondary end point, overall survival (OS). However, a post hoc analysis showed that FCA increased OS in patients younger than 65 years (3-year OS 85% vs 76%, P = .035). FCA also increased the overall response rate (88 vs 78%, P = .036), and the bone marrow minimal residual disease-negative complete remission rate (64% vs 43%, P = .016). Opportunistic infections were more frequent following FCA, but without an increase in treatment related mortality (FCA: 3.8%, FC: 4.3%). FCA improves progression-free survival in high-risk chronic lymphocytic leukemia. As anticipated, FCA is more immunosuppressive than FC, but with due vigilance, does not lead to a higher treatment-related mortality. This study was registered at www.trialregister.nl as trial no. NTR529.
- Published
- 2014
22. Short telomere length is associated withNOTCH1/SF3B1/TP53aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients
- Author
-
Richard Rosenquist, Karin E. Smedby, Ulrika Svenson, Christian H. Geisler, Göran Roos, Gunnar Juliusson, Pawel Grabowski, Nicola Cahill, Larry Mansouri, Rebeqa Gunnarsson, and Sofie Degerman
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Pathology ,Chronic lymphocytic leukemia ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,hemic and lymphatic diseases ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Receptor, Notch1 ,Survival rate ,Aged ,Retrospective Studies ,030304 developmental biology ,0303 health sciences ,Hematology ,business.industry ,Retrospective cohort study ,Middle Aged ,Ribonucleoprotein, U2 Small Nuclear ,Telomere ,Phosphoproteins ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Rate ,Clinical trial ,Leukemia ,030220 oncology & carcinogenesis ,Predictive value of tests ,Mutation ,Female ,RNA Splicing Factors ,Tumor Suppressor Protein p53 ,business ,Follow-Up Studies - Abstract
Most previous studies on telomere length (TL) in chronic lymphocytic leukemia (CLL) are based on referral cohorts including a high proportion of aggressive cases. Here, the impact of TL was analyzed in a population-based cohort of newly diagnosed CLL (n = 265) and in relation to other prognostic markers. Short telomeres were particularly associated with high-risk genetic markers, such as NOTCH1, SF3B1, or TP53 aberrations, and predicted a short time to treatment (TTT) and overall survival (OS) (both P0.0001). TL was an independent prognostic factor and subdivided patients with otherwise good-prognostic features (e.g., mutated IGHV genes, favorable cytogenetics) into subgroups with different outcome. Furthermore, in follow-up samples (n = 119) taken 5-8 years after diagnosis, TL correlated well with TL at diagnosis and remained unaffected by treatment. Altogether, these novel data indicate that short TL already at diagnosis is associated with poor outcome in CLL and that TL can be measured at later stages of the disease.
- Published
- 2013
23. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients
- Author
-
Philippe Solal-Celigny, Martin Weisser, Ru-Fang Yeh, Tobias Benthaus, Gudrun Mellert, John Catalano, Wolfgang Hiddemann, Stefan K. Bohlander, Debraj GuhaThakurta, Guillemette Duchateau-Nguyen, Purvi M. Kakadia, Tadeusz Robak, Lin Wu, Evelyn Zellmeier, Marco Montillo, Sabine Lohmann, David Dornan, Nancy Patten, Christian H. Geisler, Sim Truong, Giuseppe Palermo, Stephanie Schneider, Jan Braess, Galina Salogub, Annika Dufour, Anna Dmoszynska, and Karsten Spiekermann
- Subjects
Adult ,Male ,endocrine system diseases ,Chronic lymphocytic leukemia ,Immunology ,Down-Regulation ,Phases of clinical research ,Biochemistry ,Disease-Free Survival ,stomatognathic system ,Downregulation and upregulation ,Recurrence ,Biomarkers, Tumor ,Humans ,Medicine ,Gene Silencing ,Treatment Failure ,neoplasms ,Aged ,Regulation of gene expression ,medicine.diagnostic_test ,Gene Expression Regulation, Leukemic ,business.industry ,Point mutation ,Cell Biology ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,MicroRNAs ,Leukemia ,Disease Progression ,Cancer research ,Female ,Rituximab ,Tumor Suppressor Protein p53 ,business ,medicine.drug ,Fluorescence in situ hybridization - Abstract
In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor prognosis. So far, the impact of the various TP53 defects has not been evaluated in a large cohort of previously treated and relapsed CLL patients. Here, we present the results of TP53 gene sequencing and fluorescence in situ hybridization for del17p in a phase 3 clinical trial (REACH [Rituximab in the Study of Relapsed Chronic Lymphocytic Leukemia]). Of the 457 patients, 52 had TP53 mutations and 37 had del17p. In 24 (46%) of the TP53 mutated patients, no del17p was found and in 9 of the del17p patients, no TP53 mutation was identified. Based on a predicted proportion of TP53 disruption, a complete disruption of TP53 function, either by a combination of point mutations and/or del17p, was associated with a high risk for disease progression. Progression-free survival of patients with a heterozygous TP53 mutation was not significantly different from patients with a completely intact TP53 locus. In addition, only a complete loss of TP53 function correlated with low microRNA-34a expression levels. This trial was registered at www.clinicaltrials.gov as #NCT00090051.
- Published
- 2013
24. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2
- Author
-
Jitka Malčíková, Richard Rosenquist, Panagiotis Panagiotidis, C. Belessi, Tatiana Tzenou, P. F. Di Celle, Karla Plevová, Šárka Pospíšilová, Nicola Cahill, Anthonie Willem Langerak, Larry Mansouri, Nicholas Chiorazzi, Christian H. Geisler, Kostas Stamatopoulos, Lone B. Pedersen, Zadie Davis, Lesley-Ann Sutton, Diego Cortese, David Oscier, Panagiotis Baliakas, Evangelia Stalika, Paolo Ghia, Lydia Scarfò, Andreas Agathangelidis, Frederic Davi, Jonathan C. Strefford, Strefford, Jc, Sutton, La, Baliakas, P, Agathangelidis, A, Malcikova, J, Plevova, K, Scarfo, L, Davis, Z, Stalika, E, Cortese, D, Cahill, N, Pedersen, Lb, di Celle, Pf, Tzenou, T, Geisler, C, Panagiotidis, P, Langerak, Aw, Chiorazzi, N, Pospisilova, S, Oscier, D, Davi, F, Belessi, C, Mansouri, L, Ghia, PAOLO PROSPERO, Stamatopoulos, K, Rosenquist R. P., Ghia is joint last author, and Immunology
- Subjects
Cancer Research ,Chronic lymphocytic leukemia ,Ubiquitin-Protein Ligases ,Biology ,medicine.disease_cause ,Somatic evolution in cancer ,Polymerase Chain Reaction ,law.invention ,Inhibitor of Apoptosis Proteins ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,law ,medicine ,Biomarkers, Tumor ,Humans ,Receptor, Notch1 ,Survival rate ,Gene ,Polymerase chain reaction ,030304 developmental biology ,0303 health sciences ,Mutation ,Hematology ,DNA, Neoplasm ,Ribonucleoprotein, U2 Small Nuclear ,medicine.disease ,Phosphoproteins ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Baculoviral IAP Repeat-Containing 3 Protein ,Survival Rate ,Leukemia ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,RNA Splicing Factors ,Follow-Up Studies - Abstract
Recent studies have revealed recurrent mutations of the NOTCH1, SF3B1 and BIRC3 genes in chronic lymphocytic leukemia (CLL), especially among aggressive, chemorefractory cases. Nevertheless, it is currently unknown whether their presence may differ in subsets of patients carrying stereotyped B-cell receptors and also exhibiting distinct prognoses. Here, we analyzed the mutation status of NOTCH1, SF3B1 and BIRC3 in three subsets with particularly poor prognosis, that is, subset # 1, # 2 and # 8, aiming to explore links between genetic aberrations and immune signaling. A remarkably higher frequency of SF3B1 mutations was revealed in subset # 2 (44%) versus subset # 1 and # 8 (4.6% and 0%, respectively; P
- Published
- 2013
25. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
- Author
-
Mats Jerkeman, Kirsten Grønbæk, Peter de Nully Brown, Karin E. Smedby, Jan Delabie, Mikael Eriksson, Marja-Liisa Karjalainen-Lindsberg, Anna Laurell, Simon Husby, Outi Kuittinen, Riikka Räty, Mats Ehinger, Christian Winther Eskelund, Christian Garde, Christian H. Geisler, Herman Nilsson-Ehle, Christopher T. Workman, Christer Sundström, Eva Kimby, Erkki Elonen, Lone Bredo Pedersen, Sandra Eloranta, Niels Smedegaard Andersen, Arne Kolstad, Elisabeth Ralfkiaer, Hans Bentzen, Grete F. Lauritzsen, Hematologian yksikkö, Clinicum, Department of Medicine, Department of Oncology, Medicum, and Department of Pathology
- Subjects
Oncology ,Male ,Lymphoma, Mantle-Cell ,Clinical trials ,0302 clinical medicine ,Autologous stem-cell transplantation ,International Prognostic Index ,Recurrence ,Antineoplastic Combined Chemotherapy Protocols ,High dose therapy ,MULTICENTER TRIAL ,Remission Induction ,Hematology ,Middle Aged ,Prognosis ,HIGH-DOSE CYTARABINE ,METHOTREXATE ,3. Good health ,Treatment Outcome ,high dose therapy ,030220 oncology & carcinogenesis ,INITIAL TREATMENT ,Rituximab ,Female ,medicine.drug ,Bendamustine ,Adult ,medicine.medical_specialty ,Non-Hodgkin Lymphoma ,3122 Cancers ,PHASE-2 ,IMMUNOCHEMOTHERAPY ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,Internal medicine ,medicine ,Humans ,Mortality ,Survival analysis ,Aged ,Neoplasm Staging ,clinical trials ,PLUS RITUXIMAB ,TRANSPLANTATION ,business.industry ,Mantle Cell Lymphoma ,medicine.disease ,Surgery ,Transplantation ,Regimen ,3121 General medicine, internal medicine and other clinical medicine ,Mantle cell lymphoma ,BENDAMUSTINE ,business ,Biomarkers ,030215 immunology ,Follow-Up Studies - Abstract
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy and autologous stem cell transplantation. One such strategy is the Nordic MCL2 regimen, developed by the Nordic Lymphoma Group. We here present the 15-year updated results of the Nordic MCL2 study after a median follow-up of 114years: For all patients on an intent-to-treat basis, the median overall and progression-free survival was 127 and 85years, respectively. The MCL International Prognostic Index (MIPI), biological MIPI, including Ki67 expression (MIPI-B) and the MIPI-B including mIR-18b expression (MIPI-B-miR), in particular, significantly divided patients into distinct risk groups. Despite very long response durations of the low and intermediate risk groups, we observed a continuous pattern of relapse and the survival curves never reached a plateau. In conclusion, despite half of the patients being still alive and 40% in first remission after more than 12years, we still see an excess disease-related mortality, even among patients experiencing long remissions. Even though we consider the Nordic regimen as a very good choice of regimen, we recommend inclusion in prospective studies to explore the benefit of novel agents in the frontline treatment of MCL.
- Published
- 2016
26. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- Author
-
Mats Ehinger, Kirsten Grønbæk, Alexandra Albertsson-Lindblad, Christian H. Geisler, Mats Jerkeman, Anna Laurell, Lone Bredo Pedersen, Marja-Liisa Karjalainen-Lindsberg, J. Sundberg, Arne Kolstad, Riikka Räty, Christer Sundström, and Elisabeth Ralfkiaer
- Subjects
Bendamustine ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Immunology ,Lymphoma, Mantle-Cell ,Biochemistry ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Bendamustine Hydrochloride ,Humans ,Progression-free survival ,Lenalidomide ,Aged ,Aged, 80 and over ,business.industry ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,3. Good health ,Surgery ,CD4 Lymphocyte Count ,Thalidomide ,Treatment Outcome ,030220 oncology & carcinogenesis ,Rituximab ,Mantle cell lymphoma ,Female ,Cytomegalovirus retinitis ,Every Four Weeks ,business ,Tomography, X-Ray Computed ,030215 immunology ,medicine.drug - Abstract
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m2 IV, days 1-2 and R 375 mg/m2 IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534.
- Published
- 2016
27. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death
- Author
-
Ole Weis Bjerrum, Michael Asger Andersen, Mette K. Andersen, Carsten Utoft Niemann, Fie Juhl Vojdeman, Peter de Nully Brown, and Christian H. Geisler
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Chronic lymphocytic leukemia ,Newly diagnosed ,Infections ,Gastroenterology ,Hypogammaglobulinemia ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Agammaglobulinemia ,hemic and lymphatic diseases ,Internal medicine ,Cause of Death ,medicine ,Humans ,Stage (cooking) ,Gene Rearrangement, B-Lymphocyte ,Cause of death ,Aged ,Aged, 80 and over ,Chromosome Aberrations ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Leukemia, Lymphocytic, Chronic, B-Cell ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,Female ,Neoplasm Grading ,business ,IGHV@ ,Biomarkers ,030215 immunology ,Follow-Up Studies - Abstract
Hypogammaglobulinemia is the most common immune deficiency in chronic lymphocytic leukemia (CLL). However, the prognostic significance in terms of morbidity and mortality remains controversial. We here evaluate the significance of hypogammaglobulinemia in terms of infections, treatment-free survival (TFS), and overall survival (OS). A total of 159 consecutive, newly diagnosed patients were included for analysis. Twenty-five patients (16%) had a moderate or severe infection within one year of diagnosis, but no associations were found between low immunoglobulin (Ig) levels and infections. In multivariate analysis, we found age (>65), high Binet stage, high β2-microglobulin, and Ig deficiency to be associated with shorter OS. Decreased levels of IgM, deletion of chromosome 17p and unmutated IGHV status had independent negative impact on TFS. Thus, patients with hypogammaglobulinemia did not suffer more from infections early in the disease course, and decreased Ig had independent negative prognostic impact in CLL.
- Published
- 2016
28. Treatment of Older Patients with Mantle-Cell Lymphoma
- Author
-
Michael Uppenkamp, Vít Procházka, Catherine Thieblemont, R. Bouabdallah, Wolfgang Hiddemann, Michael Pfreundschuh, M. Andre, Marek Trneny, Michael Hallek, Martin Dreyling, Josée M. Zijlstra, Jan Walewski, Roswitha Forstpointner, Eva Hoster, Stephan Kremers, Christian H. Geisler, Vincent Ribrag, Stephan Stilgenbauer, Gérard Lepeu, Bertrand Coiffier, Laurence Sanhes, Wolfram Klapper, Ursula Vehling-Kaiser, Margaret Macro, P. Feugier, H. Tilly, Michael Unterhalt, P. J. Lugtenburg, Michal Szymczyk, Olivier Hermine, Hanneke C. Kluin-Nelemans, F. Di Raimondo, Lothar Kanz, J.K. Doorduijn, Hematology, CCA - Innovative therapy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)
- Subjects
Male ,medicine.medical_specialty ,Lymphoma, Mantle-Cell ,THERAPY ,Gastroenterology ,Maintenance Chemotherapy ,Antibodies, Monoclonal, Murine-Derived ,Maintenance therapy ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,CYCLOPHOSPHAMIDE ,medicine ,Humans ,Prospective Studies ,RITUXIMAB ,Progression-free survival ,COMBINATION ,Survival rate ,Interferon alfa ,Aged ,Aged, 80 and over ,FCM ,CHRONIC LYMPHOCYTIC-LEUKEMIA ,business.industry ,Remission Induction ,Induction Chemotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Intention to Treat Analysis ,STUDY-GROUP GLSG ,Surgery ,Fludarabine ,Survival Rate ,Doxorubicin ,Vincristine ,Prednisone ,Female ,Rituximab ,Mantle cell lymphoma ,PROSPECTIVE RANDOMIZED-TRIAL ,FLUDARABINE ,business ,Vidarabine ,Progressive disease ,PROGRESSION-FREE SURVIVAL ,medicine.drug - Abstract
BACKGROUNDThe long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.METHODSWe randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression.RESULTSOf the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P = 0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P = 0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P = 0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P = 0.005).CONCLUSIONSR-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.)
- Published
- 2012
29. IGHV3-21 Gene Frequency in a Swedish Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
- Author
-
Fergus Ryan, Karin E. Smedby, Rebeqa Gunnarsson, Richard Rosenquist, Gunnar Juliusson, Mattias Jansson, Fiona Murray, Larry Mansouri, Lesley-Ann Sutton, Christian H. Geisler, and Nicola Cahill
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Population ,Immunoglobulin Variable Region ,White People ,Cohort Studies ,Gene Frequency ,Internal medicine ,medicine ,Humans ,education ,Allele frequency ,Aged ,Neoplasm Staging ,Sweden ,education.field_of_study ,Hematology ,business.industry ,Middle Aged ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Stereotypy (non-human) ,Oncology ,Mutation ,Cohort ,Immunology ,Medical genetics ,Female ,Immunoglobulin Heavy Chains ,business ,Cohort study - Abstract
The IGHV3-21 gene has been shown to be overrepresented in Scandinavian patients with chronic lymphocytic leukemia (CLL). By investigating a population-based cohort of 337 Swedish patients with CLL, a lower (6.5%) IGHV3-21 frequency was determined relative to our previous hospital-based studies (10.1%-12.7%), yet this frequency remained higher compared to other Western CLL cohorts (2.6%-4.1%). Furthermore, we confirmed the poor outcome for patients with IGHV3-21 to be independent of mutational and stereotypy status. Background: Scandinavian patients with CLL have shown an overrepresentation of the poor-prognostic IGHV3-21 gene. Furthermore, approximately 50% of patients with IGHV3-21 carry stereotyped B-cell receptors, which implicate antigen selection in leukemogenesis. These patients have also been reported to have shorter time to progression than patients with nonstereotyped IGHV3-21. Materials and Methods: To investigate the IGHV3-21 frequency and the clinical impact of IGHV3-21 stereotypy, 337 newly diagnosed Swedish CLL patients from a population-based cohort were analyzed. Results: Interestingly, the IGHV3-21 frequency was indeed lower (6.5%) in this indolent patient cohort than in our previous hospital-based cohort studies (10.1%-12.7%). Hence, a selection bias of more-aggressive cases rendered a higher proportion of IGHV3-21 cases in our original studies. Nevertheless, the Swedish IGHV3-21 frequency still remained higher when compared with other larger European or American studies (2.6%-4.1%). Finally, we confirmed the poor outcome for IGHV3-21 patients to be independent of mutational status and found stereotypy to have no impact on survival or time to treatment. Conclusion: The Swedish geographic bias in IGHV3-21 gene frequency was validated albeit at a lower frequency than previously reported. Moreover, no prognostic value could be attributed to IGHV3-21 stereotype status.
- Published
- 2012
30. Autologous transplantation and management of younger patients with mantle cell lymphoma
- Author
-
Christian H. Geisler
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Clinical Biochemistry ,Lymphoma, Mantle-Cell ,Hematopoietic stem cell transplantation ,CHOP ,Transplantation, Autologous ,Antibodies, Monoclonal, Murine-Derived ,Autologous stem-cell transplantation ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Autologous transplantation ,Lenalidomide ,business.industry ,Remission Induction ,Age Factors ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Disease Management ,medicine.disease ,Survival Analysis ,Thalidomide ,Surgery ,Transplantation ,Treatment Outcome ,Mantle cell lymphoma ,Rituximab ,business ,medicine.drug - Abstract
Mantle cell lymphoma is traditionally conceived as one of the NHL subtypes with the worst prognosis and incurable. In responders to frontline induction with CHOP-like chemotherapy autologous stem cell transplantation (ASCT) is proven superior to interferon maintenance, but does not lead to long-term disease control. The efficacy of CHOP as induction therapy before ASCT in MCL is questioned and there is now evidence that as pretreatment before ASCT, AraC + rituximab leads to deeper remission and prolongs progression-free survival compared to rituximab + CHOP. The treatment goal of complete clinical and molecular remission in younger patients with MCL, is now within reach, based on an integrated approach of intensive AraC containing immunochemotherapy with or without subsequent ASCT, and post-treatment maintenance with rituximab or lenalidomide are now being investigated. Such an integrated approach might lead to a shift of paradigm of MCL from an incurable to a curable lymphoma.
- Published
- 2012
31. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
- Author
-
Christian H, Geisler, Arne, Kolstad, Anna, Laurell, Mats, Jerkeman, Riikka, Räty, Niels S, Andersen, Lone B, Pedersen, Mikael, Eriksson, Marie, Nordström, Eva, Kimby, Hans, Bentzen, Outi, Kuittinen, Grete F, Lauritzsen, Herman, Nilsson-Ehle, Elisabeth, Ralfkiaer, Mats, Ehinger, Christer, Sundström, Jan, Delabie, Marja-Liisa, Karjalainen-Lindsberg, Peter, Brown, Erkki, Elonen, and Johan, Vaktnäs
- Subjects
Male ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Lymphoma, Mantle-Cell ,Hematopoietic stem cell transplantation ,Transplantation, Autologous ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,Autologous stem-cell transplantation ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Cyclophosphamide ,Melphalan ,Survival rate ,Etoposide ,Aged ,Podophyllotoxin ,business.industry ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Carmustine ,Lymphoma ,Surgery ,Survival Rate ,Transplantation ,Female ,Mantle cell lymphoma ,Rituximab ,Immunotherapy ,business ,medicine.drug - Abstract
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at www.isrctn.org as ISRCTN 87866680.
- Published
- 2012
32. T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
- Author
-
Marie Nordström, Eva Kimby, Hans Hagberg, Martin Erlanson, Christer Sundström, Tuula Lehtinen, Bjørn Østenstad, Christian H. Geisler, Birgitta Sander, Herman Nilsson-Ehle, Anne Tierens, Björn E. Wahlin, Peter de Nully Brown, Martin Maisenhölder, Harald Holte, Birger Christensson, and Ola Lindén
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,T-Lymphocytes ,medicine.medical_treatment ,Follicular lymphoma ,Antineoplastic Agents ,Antibodies, Monoclonal, Murine-Derived ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,In patient ,Lymphoma, Follicular ,Survival analysis ,Aged ,Chemotherapy ,biology ,business.industry ,Interferon-alpha ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Lymphocyte Subsets ,Lymphoma ,Treatment Outcome ,Monoclonal ,biology.protein ,Rituximab ,Antibody ,business ,medicine.drug - Abstract
Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is unknown. Experimental Design: Using flow cytometry, we evaluated the T cells in tumors and/or blood in a total of 250 follicular lymphoma patients included in two Nordic Lymphoma Group randomized trials that compared single rituximab with IFN-α2a–rituximab combinations. Results: In univariate analysis, higher levels of CD3+, CD4+, and CD8+ T cells in both tumors and blood correlated with superior treatment responses, and in multivariate analysis, tumor-CD3+ (P = 0.011) and blood-CD4+ (P = 0.029) cells were independent. CD4+ cells were favorable regardless of treatment arm, but CD8+ cells were favorable only in patients treated with single rituximab, because IFN-α2a improved responses especially in patients with low CD8+ cell levels. Higher levels of blood-CD3+ (P = 0.003) and blood-CD4+ (P = 0.046) cells predicted longer overall survival, and higher levels of blood-CD8+ cells longer times to next treatment (P = 0.046). Conclusions: We conclude that therapeutic effects of rituximab are augmented by tumor-associated T cells for rapid responses and by systemic T cells for sustained responses. CD4+ and CD8+ cells are both favorable in patients treated with rituximab. IFN-α2a abrogates the negative impact of few CD8+ cells. Clin Cancer Res; 17(12); 4136–44. ©2011 AACR.
- Published
- 2011
33. The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL)
- Author
-
Barbara Eichhorst, Michael Gregor, Christian H. Geisler, Arnon P. Kater, Patrick Thornton, Niemann Carsten, Marinus H. J. van Oers, Tamar Tadmor, Eric Eldering, Matthias Ritgen, Stephan Stilgenbauer, Karl Anton Kreuzer, Michael Hallek, Kirsten Fischer, Jasmin Bahlo, Von Tresckow Julia, Moritz Fürstenau, and Anna-Maria Fink
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Standard of care ,business.industry ,Chronic lymphocytic leukemia ,Tp53 mutation ,medicine.disease ,First line treatment ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Chemoimmunotherapy ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,business - Abstract
TPS7582Background: Chemoimmunotherapy (CIT) is still standard of care in first line treatment of fit CLL patients (pts) without del(17p) or TP53 mutation. However, CIT is often associated with side...
- Published
- 2018
34. Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study
- Author
-
Sebastian Grosicki, Marinus H. J. van Oers, Lukas Smolej, Tommaso Stefanelli, Mario Petrini, Mark-David Levin, Jaclyn Davis, Fritz Offner, Petra Hoever, Hiya Banerjee, and Christian H. Geisler
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,Relapsed chronic lymphocytic leukemia ,Interim analysis ,Ofatumumab ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Internal medicine ,medicine ,In patient ,030212 general & internal medicine ,Progression-free survival ,business ,neoplasms - Abstract
7517Background: An interim analysis of the PROLONG phase 3 study in patients (pts) with CLL showed a significant increase in progression free survival (PFS) with OFA maintenance without unexpected ...
- Published
- 2018
35. Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment
- Author
-
Gunnar Juliusson, Alexander Schmitz, Christian H. Geisler, G W Jürgensen, Per Hörnsten, Gunnar Kvalheim, Kari Remes, Stein Kvaløy, Martin Boegsted, O J Bergmann, Lars Møller Pedersen, Hans Erik Johnsen, and Eeva Juvonen
- Subjects
Male ,Oncology ,Transplantation Conditioning ,Lymphoma ,medicine.medical_treatment ,Priming (immunology) ,Antigens, CD34 ,Pilot Projects ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Granulocyte Colony-Stimulating Factor ,Stem Cell Factor ,biology ,Graft Survival ,Hematology ,Middle Aged ,Hematopoietic Stem Cell Mobilization ,Recombinant Proteins ,3. Good health ,Granulocyte colony-stimulating factor ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Neutropenia ,Filgrastim ,Transplantation, Autologous ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Ancestim ,Aged ,Peripheral Blood Stem Cell Transplantation ,Transplantation ,Chemotherapy ,business.industry ,medicine.disease ,Thrombocytopenia ,Surgery ,Clinical trial ,biology.protein ,business ,030215 immunology - Abstract
Udgivelsesdato: 2010-May-3 SCF has been shown to synergize with G-CSF to mobilize CD34(+) PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to receive recombinant methionyl human SCF (ancestim, r-metHuSCF) in combination with recombinant methionyl human G-CSF (filgrastim, r-metHuG-CSF) (experimental arm A) or routine chemotherapy plus filgrastim (conventional arm B). The primary objective was to evaluate the side effects and toxicity during priming and mobilization. The secondary objectives were efficacy by the level of blood-circulating PBPCs, the number of harvest days and the time to three-lineage engraftment after autografting. First, during priming 5 patients had 8 serious events, 4 in each arm. A summary of all adverse events revealed 30 (94%) patients suffering from 132 events of all grading. Second, neutropenia and thrombocytopenia was documented in arm B. Third, 9/14 (64%) patients in arm A reached the target of 5 million CD34(+) cells/kg body weight (bw) compared with 13/15 (87%) in arm B. The results represent the first randomized trial of growth factor plus chemotherapy priming and indicate that a formal phase III trial very unlikely may challenge chemotherapy plus r-metHuG-CSF priming in candidates for high-dose therapy.Bone Marrow Transplantation advance online publication, 3 May 2010; doi:10.1038/bmt.2010.84.
- Published
- 2010
36. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- Author
-
John Catalano, Peter Ganly, Tadeusz Robak, M. Wayne Saville, Sergey I. Moiseev, Anna Dmoszynska, Ilya Zyuzgin, Christian H. Geisler, Krzysztof Warzocha, Nancy Valente, Philippe Solal-Celigny, Caroline Dartigeas, Javier Loscertales, Marco Montillo, Jörg Maurer, Michael Wenger, Loree Larratt, Myriam Mendila, Boris V. Afanasiev, and András Rosta
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Cyclophosphamide ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,Ofatumumab ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,chemistry.chemical_compound ,Chemoimmunotherapy ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Aged ,Aged, 80 and over ,CD20 ,Chemotherapy ,biology ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Fludarabine ,chemistry ,Retreatment ,Immunology ,Quality of Life ,biology.protein ,Female ,Rituximab ,business ,Vidarabine ,medicine.drug - Abstract
Purpose Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL. Patients and Methods This international, multicenter, randomized trial compared six cycles of rituximab plus fludarabine and cyclophosphamide (R-FC) with six cycles of fludarabine and cyclophosphamide alone (FC) in patients with previously treated CLL. A total of 552 patients with Binet stage A (1%), B (59%), or C (31%) disease entered the study and were randomly assigned to receive R-FC (n = 276) or FC (n = 276). Results After a median follow-up time of 25 months, rituximab significantly improved progression-free survival in patients with previously treated CLL (hazard ratio = 0.65; P < .001; median, 30.6 months for R-FC v 20.6 months for FC). Event-free survival, response rate, complete response rate, duration of response, and time to new CLL treatment or death were also significantly improved. Although the rates of adverse events, grade 3 or 4 events, and serious adverse events were slightly higher in the R-FC arm, R-FC was generally well tolerated, with no new safety findings and no detrimental effect on quality of life. Conclusion R-FC significantly improved the outcome of patients with previously treated CLL.
- Published
- 2010
37. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
- Author
-
Marja-Liisa Karjalainen-Lindsberg, Anne Marie Boesen, Mats Jerkeman, Riikka Räty, Christian H. Geisler, Eva Kimby, Anna Laurell, Grete F. Lauritzsen, Mats Ehinger, Marie Nordström, Erkki Elonen, Christer Sundström, Arne Kolstad, Elisabeth Ralfkiaer, Outi Kuittinen, Jan Delabie, Peter de Nully Brown, Herman Nilsson-Ehle, and Mikael Eriksson
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Immunology ,Lymphoma, Mantle-Cell ,Transplantation, Autologous ,Biochemistry ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,International Prognostic Index ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Survival rate ,Hematology ,business.industry ,Cell Biology ,medicine.disease ,Chemotherapy regimen ,3. Good health ,Lymphoma ,Surgery ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Transplantation ,Ki-67 Antigen ,030220 oncology & carcinogenesis ,Female ,Mantle cell lymphoma ,business ,Stem Cell Transplantation ,030215 immunology - Abstract
Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.
- Published
- 2010
38. Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
- Author
-
Erkki Elonen, Marie Nordström, Jaan Väärt, Mats Jerkeman, Niels Smedegaard Andersen, Mikael Eriksson, Grete F. Lauritzsen, Beatrice Malmer, Anna Laurell, Roald Ekanger, Lone Bredo Pedersen, Lars Møller Pedersen, Anne Marie Boesen, Christian H. Geisler, Herman Nilsson-Ehle, Susanne Fredén, and Arne Kolstad
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Neoplasm, Residual ,Antineoplastic Agents ,Lymphoma, Mantle-Cell ,Polymerase Chain Reaction ,Transplantation, Autologous ,Drug Administration Schedule ,Antibodies, Monoclonal, Murine-Derived ,Autologous stem-cell transplantation ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Gene Rearrangement ,business.industry ,Antibodies, Monoclonal ,Gene rearrangement ,medicine.disease ,Survival Analysis ,Minimal residual disease ,Surgery ,Lymphoma ,Treatment Outcome ,medicine.anatomical_structure ,Feasibility Studies ,Rituximab ,Mantle cell lymphoma ,Bone marrow ,Immunoglobulin Heavy Chains ,business ,Progressive disease ,Stem Cell Transplantation ,medicine.drug - Abstract
Purpose Minimal residual disease (MRD) is predictive of clinical progression in mantle-cell lymphoma (MCL). According to the Nordic MCL-2 protocol we prospectively analyzed the efficacy of pre-emptive treatment using rituximab to MCL patients in molecular relapse after autologous stem cell transplantation (ASCT). Patients and Materials MCL patients enrolled onto the study, who had polymerase chain reaction (PCR) detectable molecular markers and underwent ASCT, were followed with serial PCR assessments of MRD in consecutive bone marrow and peripheral blood samples after ASCT. In case of molecular relapse with increasing MRD levels, patients were offered pre-emptive treatment with rituximab 375 mg/m2 weekly for 4 weeks. Results Of 160 MCL patients enrolled, 145 underwent ASCT, of whom 78 had a molecular marker. Of these, 74 were in complete remission (CR) and four had progressive disease after ASCT. Of the CR patients, 36 underwent a molecular relapse up to 6 years (mean, 18.5 months) after ASCT. Ten patients did not receive pre-emptive treatment mainly due to a simultaneous molecular and clinical relapse, while 26 patients underwent pre-emptive treatment leading to reinduction of molecular remission in 92%. Median molecular and clinical relapse-free survival after pre-emptive treatment were 1.5 and 3.7 years, respectively. Of the 38 patients who remain in molecular remission for now for a median of 3.3 years (range, 0.4 to 6.6 years), 33 are still in clinical CR. Conclusion Molecular relapse may occur many years after ASCT in MCL, and PCR based pre-emptive treatment using rituximab is feasible, reinduce molecular remission, and may prevent clinical relapse.
- Published
- 2009
39. Sézary syndrome: phenotypic and functional characterization of the neoplastic cells
- Author
-
Torben Plesner, Gunhild Lange Wantzin, Vagn Andersen, Elisabeth Ralfkiaer, Christian H. Geisler, Joergen K. Larsen, and Kristian Thomsen
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Skin Neoplasms ,Lymphoma ,medicine.drug_class ,T-Lymphocytes ,Cell ,Immunoglobulins ,Biology ,Monoclonal antibody ,medicine ,Humans ,Sezary Syndrome ,Cytotoxic T cell ,Lymph node ,Aged ,Skin ,Cutaneous T-cell lymphoma ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,medicine.disease ,Phenotype ,In vitro ,medicine.anatomical_structure ,Immunohistochemistry ,Female ,Lymph Nodes - Abstract
Phenotypic properties of the neoplastic cells in skin, blood and lymph node specimens from 5 patients with the Sezary syndrome were examined by immuno-enzymatic and -fluorescence labelling of cells and tissue sections with a monoclonal antibody panel. In 3 cases, the in vitro functional properties of the neoplastic cells (isolated from blood specimens) were also analysed using a reverse plaque-forming cell assay. 3 different immunological categories were identified as follows: (1) T-helper/inducer neoplasms (3 patients); (2) T-suppressor/cytotoxic neoplasms (1 patient); and (3) neoplastic T-cells demonstrating characteristics consistent with a concept of their derivation from inducible suppressor T-cells (1 patient). These data provide conclusive evidence that Sezary syndrome is heterogeneous with respect to the immunological characteristics of the neoplastic cells.
- Published
- 2009
40. Lack of prognostic significance of T-lymphocyte subset counts in B-cell chronic lyrnphocytic leukaemia
- Author
-
Christian H. Geisler, Mads Hansen, Torben Plesner, Jørgen K. Larsen, and Mogens Mørk Hansen
- Subjects
Male ,medicine.drug_class ,T-Lymphocytes ,Chronic lymphocytic leukemia ,Cell ,Immunoglobulins ,Biology ,Monoclonal antibody ,Peripheral blood mononuclear cell ,Flow cytometry ,Andrology ,medicine ,Humans ,Cytotoxic T cell ,B cell ,B-Lymphocytes ,medicine.diagnostic_test ,Antibodies, Monoclonal ,Hematology ,General Medicine ,T lymphocyte ,Flow Cytometry ,Prognosis ,medicine.disease ,Leukemia, Lymphoid ,medicine.anatomical_structure ,Immunology ,Female - Abstract
In the 50 newly diagnosed, unselected, untreated B-CLL patients, the absolute numbers of blood T cells, T-helper cells, and T-suppressor/cytotoxic cells were determined by flow cytometric counting of mononuclear cells labelled with the monoclonal antibodies Leu5 (T cells), Leu3a (T-helper cells), and Leu2a (T-suppressor/cytotoxic cells). These estimations and the serum concentrations of IgG, IgA, and IgM were correlated to clinical stage (International Workshop System) and pretreatment observation time. For all patients together, the mean counts of Leu5 +, Leu3 +, and Leu2 + cells were significantly increased compared with the mean counts in 12 healthy controls (Mann-Whitney). In patients with advanced disease (stage B + C), both T-subset mean cell counts were significantly increased, whereas in patients with early-stage disease (stage A), although some high T-helper cell counts were noted, only the T-suppressor/ cytotoxic mean cell count increase reached significance. Thus a trend was observed of a more frequent T-suppressor/cytotoxic cell predominance in early-stage disease, which is the opposite of the findings in most other prognostic studies. However, there was no significant difference in pre-treatment observation time according to T-helper: T-suppressor cell ratio below vs. above 1.0, irrespective of stage, whereas according to clinical stage, the pretreatment observation time in stage A was highly significantly longer than in stage B + C (logrank test). Thus, no independent prognostic significance of T-subset counts was found as judged by pretreatment observation time. No correlation was found between the occurrence of hypogammaglobulinaemia, T-subset ratios or T-subset counts. In 24 patients, the number of Leu7+ cells (natural killer/ cytotoxic cells) were also counted and found significantly increased compared with normal values.
- Published
- 2009
41. B-cell chronic lymphocytic leukaemia: Clonal chromosome abnormalities and prognosis in 89 cases
- Author
-
Mogens Mørk Hansen, Preben Philip, and Christian H. Geisler
- Subjects
Pathology ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Chromosome Disorders ,Trisomy ,medicine ,Humans ,Lymphocytes ,B cell ,Phytohaemagglutinin ,Chromosome Aberrations ,Chromosomes, Human, Pair 12 ,biology ,Pokeweed mitogen ,Cytogenetics ,Chromosome ,Karyotype ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Survival Analysis ,Clone Cells ,Phenotype ,medicine.anatomical_structure ,Karyotyping ,biology.protein ,Mitogens - Abstract
The results of cytogenetic studies are reported in 89 patients with B-cell CLL. LPS (E. coli lipopolysaccharide), PWM (pokeweed mitogen), PHA (phytohaemagglutinin), EBV (Epstein-Barr virus), TPA (phorbol 12-myristate 13-acetate), and LA (leucoagglutinin) were used as mitogens. Mitoses were obtained from 78 cases. Clonal aberrations could be demonstrated in 26 cases. Trisomy 12 was the most frequent finding (8 cases) and was sole abnormality in 4 cases. Chromosomes #14, #17, and #11 were involved in structural aberrations in 5, 7, and 7 cases respectively, but a t(11;14)(q13;q32) was the only structural aberration seen more than once. The median observation time was 47 months (range 1-87). The presence of clonal abnormalities did not influence survival significantly, either when calculated from diagnosis or from cytogenetic analysis. Patients with more than one aberration, however, had a significantly shorter survival than patients with normal mitoses only (p less than 0.05). The survival of 8 patients with trisomy 12 (in 4 as sole abnormality) was not different from that of patients with normal mitoses only.
- Published
- 2009
42. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- Author
-
Marie Nordström, Outi Kuittinen, R. Langholm, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, Anne Marie Boesen, Erkki Elonen, Mikael Eriksson, Mats Jerkeman, Arne Kolstad, Lone Bredo Pedersen, Christer Sundström, Peter de Nully Brown, Herman Nilsson-Ehle, Mats Ehinger, Grete F. Lauritzsen, Elisabeth Ralfkiaer, Måns Åkerman, Christian H. Geisler, Eva Kimby, Niels Smedegaard Andersen, and Anna Laurell
- Subjects
Adult ,Male ,Oncology ,Vincristine ,medicine.medical_specialty ,Time Factors ,Clinical Trials and Observations ,medicine.medical_treatment ,Immunology ,Lymphoma, Mantle-Cell ,Biochemistry ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Progression-free survival ,Etoposide ,Aged ,Chemotherapy ,business.industry ,Stem Cells ,Bone Marrow Purging ,Cell Biology ,Hematology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,3. Good health ,Surgery ,Transplantation ,Ki-67 Antigen ,Treatment Outcome ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Cytarabine ,Refractory Mantle Cell Lymphoma ,Female ,Mantle cell lymphoma ,Immunotherapy ,business ,030215 immunology ,medicine.drug - Abstract
Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + high-dose cytarabine. Responders received high-dose chemotherapy with BEAM or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL-1 trial, the event-free, overall, and progression-free survival, the duration of molecular remission, and the proportion of PCR-negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure. Registered at www.isrctn.org as #ISRCTN 87866680.
- Published
- 2008
43. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure
- Author
-
Peter Gimsing, Christian H. Geisler, Bendt Nielsen, and Lene Meldgaard Knudsen
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Renal function ,Hematopoietic stem cell transplantation ,Disease-Free Survival ,Autologous stem-cell transplantation ,Renal Dialysis ,medicine ,Humans ,Autologous transplantation ,Renal Insufficiency ,Multiple myeloma ,Dialysis ,Aged ,Chemotherapy ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Transplantation ,Treatment Outcome ,Creatinine ,Female ,Multiple Myeloma ,business - Abstract
The impact of renal failure on prognosis of multiple myeloma patients treated with high-dose chemotherapy and stem cell support is incompletely studied. A total of 137 patients received high-dose chemotherapy with autologous transplantation at our centre. The patient population was divided into three groups based on their estimated creatinine clearance (Ccr); renal failure defined as Ccr < 60 mL/min: Group A: normal renal function both at diagnosis and at transplant (n = 78), Group B: renal failure at diagnosis but normal renal function at transplant (n = 30), Group C: renal failure both at diagnosis and at transplant (n = 29). There were no differences in the number of stem cells harvested, time to engraftment or response to transplantation between the groups. Ten of the patients in Group C had a normalisation of renal function post-transplant. Significantly longer hospitalisation, increased use of blood products and increased number of infections were seen in Group C compared to Groups A and B. The transplant-related mortality was 17% in Group C compared to 0% and 1% in Groups B and A respectively. Eight patients were on dialysis during transplant and four of these died within the first 100 d post-transplant. Disease response was similar in the three groups. Overall survival was significantly longer in Group A than in Groups B and C. High-dose chemotherapy with autologous transplantation is feasible in MM with renal failure. Whereas patients with moderate renal insufficiency seem to benefit from this treatment, patients in need for dialysis at the time of transplant must be carefully evaluated before proceeding to high-dose chemotherapy.
- Published
- 2005
44. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
- Author
-
Riikka Räty, Mats Jerkeman, Arne Kolstad, Anna Laurell, and Christian H. Geisler
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Treatment outcome ,ComputingMilieux_LEGALASPECTSOFCOMPUTING ,Lymphoma, Mantle-Cell ,Antibodies, Monoclonal, Murine-Derived ,03 medical and health sciences ,0302 clinical medicine ,High dose cytarabine ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Treatment Failure ,Hematology ,business.industry ,Cytarabine ,medicine.disease ,3. Good health ,Lymphoma ,First line treatment ,Treatment Outcome ,Cancer and Oncology ,030220 oncology & carcinogenesis ,Immunology ,Rituximab ,Mantle cell lymphoma ,business ,030215 immunology ,medicine.drug - Abstract
The Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial (MCL5) was launched in 2011 (EudraCT 2011-001557-85), aimed to improve the outcome of younger patients with MCL with high Mantle Cell Lymphoma...
- Published
- 2013
45. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant
- Author
-
Niels Smedegaard Andersen, Lone Bredo Pedersen, Kaarle Franssila, Mikael Eriksson, Arne Kolstad, Ruth Langholm, Elisabeth Ralfkiaer, A. Johnson, Måns Åkerman, Christian H. Geisler, Outi Kuittinen, and Erkki Elonen
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,Hematology ,business.industry ,medicine.medical_treatment ,Induction chemotherapy ,General Medicine ,CHOP ,medicine.disease ,3. Good health ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Mantle cell lymphoma ,Clinical significance ,Stem cell ,business ,030215 immunology - Abstract
Objective: The aim of the first Nordic mantle cell lymphoma (MCL) protocol was to study the clinical significance of an augmented CHOP induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) and to examine the prognostic significance of stem cell contamination rates in newly diagnosed patients with MCL. Patients and methods: Forty-one newly diagnosed patients below 66 yr were enrolled and given three series of an augmented CHOP regimen. Responders underwent stem cell mobilization with a fourth course of CHOP, stem cell harvest and ASCT. Stem cell purging was optional in the protocol and followed the routine of each participating centre. The number of tumour cells in the reinfused autografts was estimated by flow cytometry or quantitative PCR. Results: Induction therapy led to complete remission (CR) in 11 of 41 patients (27%), partial remission (PR) in 20 of 41 patients (49%) and no response in nine patients (22%), whereas one patient was not evaluable. Twenty-seven of the 31 responders underwent ASCT and 24 achieved or maintained a CR. The overall and failure-free 4-yr survival on intention-to-treat basis were 51% and 15%, respectively. Among the transplanted patients, a significantly increased failure-free (P < 0.03) and overall survival (P = 0.03) was noted among patients transplanted in CR compared with PR, respectively. By contrast, reinfusion of highly variable numbers of tumour cells with the autografts (range 0.71-80 x 10(6) tumour cells), did not affect outcome. Conclusion: In MCL, an important strategy to improve the outcome will be to intensify the induction chemotherapy. (Less)
- Published
- 2003
46. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study
- Author
-
Maija Itälä, Eeva Juvonen, Kari Remes, Eva Kimby, Christian H. Geisler, Geir E. Tjønnfjord, and Karin Karlsson
- Subjects
Oncology ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,Monoclonal antibody ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,030304 developmental biology ,0303 health sciences ,Lymphocytic leukaemia ,biology ,business.industry ,Hematology ,General Medicine ,Immunotherapy ,medicine.disease ,3. Good health ,Leukemia ,030220 oncology & carcinogenesis ,Immunology ,Monoclonal ,biology.protein ,Rituximab ,Antibody ,business ,medicine.drug - Abstract
Objectives: This prospective multicentre study was conducted to assess the efficacy of the monoclonal anti-CD20 antibody rituximab in patients with chronic lymphocytic leukaemia (CLL). Secondary ob ...
- Published
- 2002
47. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanism
- Author
-
Anne Mette Buhl, Irene M. Pedersen, Pia Klausen, Christian H. Geisler, and Jesper Jurlander
- Subjects
MAP Kinase Signaling System ,Chronic lymphocytic leukemia ,p38 mitogen-activated protein kinases ,Immunology ,Antineoplastic Agents ,Apoptosis ,Biology ,p38 Mitogen-Activated Protein Kinases ,Biochemistry ,Antibodies, Monoclonal, Murine-Derived ,Antigen ,immune system diseases ,hemic and lymphatic diseases ,Tumor Cells, Cultured ,medicine ,Humans ,Phosphorylation ,Protein kinase A ,Antibody-dependent cell-mediated cytotoxicity ,CD20 ,Antibodies, Monoclonal ,Cell Biology ,Hematology ,Antigens, CD20 ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Enzyme Activation ,Cancer research ,biology.protein ,Mitogen-Activated Protein Kinases ,Signal transduction ,CD5 ,Rituximab - Abstract
Antibodies against CD20 can activate complement and induce antibody-dependent cellular cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis. In this study, the expression and function of CD20 on B-cell chronic lymphocytic leukemia (B-CLL) cells were analyzed. Flow cytometric analysis demonstrated that B-CLL cells express CD20 with a fluorescence intensity that is significantly weaker than that of normal CD5+ and CD5− B cells and that of malignant CD5− low-grade non-Hodgkin lymphoma cells. A small population of cells from healthy donors that have an expression pattern of CD5 and CD20 identical to that of B-CLL cells were identified, and this population was confirmed to be of T lineage, not B lineage. Culture of freshly isolated B-CLL cells in the presence of the chimeric anti-CD20 antibody rituximab and a cross-linking F(ab)2 fragment, resulted in dose- and time-dependent induction of apoptosis. The induction of apoptosis occurred under conditions in which the influence of complement activation and ADCC was negligible. Cross-linking of rituximab induced strong and sustained phosphorylation of the 3 mitogen activated protein (MAP) kinases c-Jun NH2-terminal protein kinase, extracellular signal–regulated kinase, and p38. Introduction of the p38 inhibitor SB203580 into the system completely blocked signaling downstream of p38, as evidenced by the absence of MAPKAP K2 activity, and significantly reduced the degree of anti-CD20–induced apoptosis. These results demonstrate that cross-linking of rituximab bound to CD20 on freshly isolated B-CLL cells induces apoptosis through a signaling pathway that is dependent on p38 MAP-kinase activation.
- Published
- 2002
48. [In Process Citation]
- Author
-
Carsten U, Niemann and Christian H, Geisler
- Published
- 2014
49. Treating chronic lymphocytic leukemia with a combination of rituximab and alemtuzumab: a 'successful couple,' but are they still relevant together?
- Author
-
Aaron Polliack, Christian H. Geisler, and Tamar Tadmor
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,business.industry ,Chronic lymphocytic leukemia ,Hematology ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Alemtuzumab ,Humans ,Rituximab ,Female ,business ,medicine.drug - Published
- 2014
50. PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia
- Author
-
Michael Wenger, Loree Larratt, Nancy Yu, Christian H. Geisler, Galina Salogub, Viktor Rossiev, Johannes Bloehdorn, Javier Loscertales, Martin Weisser, Ru-Fang Yeh, Anna Dmoszynska, Giuseppe Palermo, David Dornan, Xiaoyan Shi, Tri Quang Nguyen, Annika Dufour, Tadeusz Robak, Marco Montillo, Axel Benner, Kirsten Fischer, Anna-Maria Fink, Philippe Solal-Celigny, Krzysztof Warzocha, John Catalano, Isabelle Bence-Bruckler, Susanna Stinson, Hartmut Döhner, Stephan Stilgenbauer, Michael Hallek, Raymonde Busch, Nancy Valente, and Guillemette Duchateau-Nguyen
- Subjects
Oncology ,medicine.medical_specialty ,Cyclophosphamide ,Chronic lymphocytic leukemia ,Immunology ,Gene Expression ,Biochemistry ,Disease-Free Survival ,Antibodies, Monoclonal, Murine-Derived ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,RNA, Messenger ,RNA, Neoplasm ,Proportional Hazards Models ,Retrospective Studies ,business.industry ,Proportional hazards model ,Cell Biology ,Hematology ,medicine.disease ,Combined Modality Therapy ,Leukemia, Lymphocytic, Chronic, B-Cell ,Fludarabine ,Leukemia ,Focal Adhesion Kinase 1 ,Monoclonal ,Cancer research ,Biomarker (medicine) ,Rituximab ,Immunotherapy ,business ,Vidarabine ,medicine.drug - Abstract
Addition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined. We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL. An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naive patients. Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models. REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with significant improvements in progression-free survival, independent of known prognostic factors in a multivariate model. Examination of PTK2 gene expression in CLL8 patients yielded similar results. Furthermore, PTK2 inhibition blunted R-dependent cell death in vitro. This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC. PTK2 expression may be a useful biomarker for patient selection in future trials. These trials were registered at www.clinicaltrials.gov as #NCT00090051 (REACH) and #NCT00281918 (CLL8).
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.